<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Postoperative nausea and vomiting
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Postoperative nausea and vomiting
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Postoperative nausea and vomiting
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jessica Feinleib, MD, PhD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Lori H Kwan, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Ammar Yamani, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Natalie F Holt, MD, MPH
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Andrew Davidson, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Marianna Crowley, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jan 17, 2024.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H959820015">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Nausea, vomiting, and retching frequently complicate recovery from anesthesia. Postoperative nausea and vomiting (PONV) is a patient-important outcome; patients often rate PONV as worse than postoperative pain [
         <a href="#rid1">
          1
         </a>
         ]. PONV usually resolves or is treated without sequelae, but may require unanticipated hospital admission and delay recovery room discharge [
         <a href="#rid2">
          2,3
         </a>
         ]. In addition, vomiting or retching can result in wound dehiscence, esophageal rupture, aspiration, dehydration, increased intracranial pressure, and pneumothorax.
        </p>
        <p>
         The term PONV is typically used to describe nausea and/or vomiting or retching in the post-anesthesia care unit (PACU) or in the immediate 24 postoperative hours. Postdischarge nausea and vomiting (PDNV) refers to symptoms that occur after discharge for outpatient procedures. Postoperative vomiting (POV) is usually measured and discussed in children, rather than PONV, because nausea may be difficult to assess in young children.
        </p>
        <p>
         This topic will discuss the risk factors for PONV, preventive strategies, and treatment of PONV in adults and children.
        </p>
        <p class="headingAnchor" id="H2239430484">
         <span class="h1">
          PATHOPHYSIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Nausea and vomiting may be induced through a variety of central and peripheral mechanisms. (See
         <a class="medical medical_review" href="/z/d/html/2537.html" rel="external">
          "Approach to the adult with nausea and vomiting", section on 'Pathophysiology'
         </a>
         .)
        </p>
        <p>
         Five principle neurotransmitter receptors mediate nausea and vomiting: muscarinic M1, dopamine D2, histamine H1,
         <sub>
         </sub>
         5-hydroxytryptamine (HT)-3 serotonin, and neurokinin 1 (NK1) – substance P [
         <a href="#rid4">
          4
         </a>
         ]. All of these receptors may be targets for prevention or treatment of PONV. The pathophysiologic pathways for PONV are shown in a figure  (
         <a class="graphic graphic_figure graphicRef110527" href="/z/d/graphic/110527.html" rel="external">
          figure 1
         </a>
         ). (See
         <a class="local">
          'Antiemetics'
         </a>
         below.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Central mechanisms
         </strong>
         – Nausea and emesis can be triggered by higher cortical centers communicating with the central pattern generator (formerly called the vomiting center) in the medulla. In the perioperative period, fear, pain, anxiety, conditioned nausea related to environmental cues, and stimulation of the vestibular system are central stimuli that may cause nausea and vomiting. As an example, during tympanoplasty, surgical stimulation of the vestibular system, transmitted via the H
         <sub>
          1
         </sub>
         histamine and M
         <sub>
          1
         </sub>
         acetylcholine receptors, may result in profound PONV [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Peripheral mechanisms
         </strong>
         –
         <strong>
         </strong>
         Direct gastric stimulation from gastric trauma, blood, or toxins induces release of substance P and serotonin from enterochromaffin cells, thereby activating the vagal and splanchnic nerve 5-HT
         <sub>
          3
         </sub>
         receptors [
         <a href="#rid6">
          6
         </a>
         ]. Vagal and splanchnic nerve afferents terminate in the nucleus tractus solitarius in the brain stem, near or within the area postrema (also called the chemoreceptor trigger zone). Bowel surgery and blood in the gastrointestinal tract from oral or ear, nose, and throat surgery may cause nausea and vomiting via this pathway, though the mechanisms by which serotonergic stimuli cause nausea and vomiting are incompletely understood.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Drugs and toxins
         </strong>
         –
         <strong>
         </strong>
         The molecular and neural mechanisms by which drugs and toxins, including anesthetics and opioids, cause nausea and vomiting are complex and incompletely understood [
         <a href="#rid7">
          7
         </a>
         ]. Both opioids and inhalation anesthetics may cause nausea and vomiting by stimulation of the area postrema at the base of the fourth ventricle in the medulla. The area postrema then communicates with the central pattern generator via dopamine and serotonin to trigger the vomiting reflex [
         <a href="#rid8">
          8,9
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H712007825">
         <span class="h1">
          RISK FACTORS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Without prophylaxis, PONV occurs in approximately 30 percent of children and adults after anesthesia [
         <a href="#rid10">
          10-13
         </a>
         ]. The risk of PONV for an individual patient varies widely; the rate of PONV may be as high as 80 percent in high-risk patients [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p>
         The incidence of PONV varies with patient factors, anesthetic choices, and possibly the type of surgery.
        </p>
        <p class="headingAnchor" id="H3592868051">
         <span class="h2">
          Patient risk factors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patient characteristics that increase the risk of PONV include the following, in decreasing order of risk:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Preoperative nausea and vomiting
         </strong>
         – PONV may be the result of a condition that was causing nausea and vomiting prior to surgery (eg, renal colic).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Female gender
         </strong>
         –
         <strong>
         </strong>
         Female gender is the most reliable patient-specific predictor for PONV [
         <a href="#rid14">
          14,15
         </a>
         ]. A meta-analysis of 22 prospective studies including over 95,000 adults found that female gender was the strongest overall predictor for PONV (odds ratio [OR] 2.57) [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In children, prior to puberty, female gender does not increase the risk of PONV [
         <a href="#rid16">
          16-18
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          History of PONV or motion sickness
         </strong>
         –
         <strong>
         </strong>
         Prior PONV and/or motion sickness increase the risk of PONV in adults (OR 2.09) [
         <a href="#rid12">
          12,14,15,19
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In children, both a prior history of PONV or postoperative vomiting (POV) and a history of PONV or POV in a parent or sibling increase the risk of POV/PONV [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Nonsmoking
         </strong>
         –
         <strong>
         </strong>
         Nonsmoking status is an independent risk factor for PONV (OR 1.82) [
         <a href="#rid12">
          12,14,15,20
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Smoking status does not usually apply to children, and the risk of POV/PONV in children exposed to secondhand smoke has not been studied.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Age
         </strong>
         –
         <strong>
         </strong>
         Most studies have reported a slight, progressive decrease in PONV in adults with increasing age [
         <a href="#rid10">
          10,14,21
         </a>
         ]. A prospective study including approximately 2200 patients who underwent general anesthesia reported that age &lt;50 was a risk factor for PONV in the post-anesthesia care unit (PACU) (OR 1.79) and postdischarge nausea and vomiting (PDNV) (OR 2.17) [
         <a href="#rid21">
          21
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In children, young age appears to be protective. POV rarely occurs in children &lt;3 years of age, and increases in frequency with age &gt;3, decreasing again with puberty [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Chemotherapy-induced nausea and vomiting
         </strong>
         – A history of chemotherapy-induced nausea and vomiting (CINV) may increase the risk of PONV (OR 3.15) [
         <a href="#rid22">
          22
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1150.html" rel="external">
          "Pathophysiology and prediction of chemotherapy-induced nausea and vomiting"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2162413264">
         <span class="h2">
          Anesthetic factors
         </span>
         <span class="headingEndMark">
          —
         </span>
         A number of anesthetic factors have been associated with PONV, some of which may be modified to reduce risk.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Anesthetic technique
         </strong>
         –
         <strong>
         </strong>
         General anesthesia is associated with a higher incidence of PONV compared with purely regional anesthesia [
         <a href="#rid12">
          12
         </a>
         ]. Regional anesthesia, in both adults and children, may reduce PONV by reducing opioid administration for postoperative pain.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Volatile anesthetics versus total intravenous anesthesia
         </strong>
         –
         <strong>
         </strong>
         The use of volatile anesthetics is an important risk factor for PONV [
         <a href="#rid12">
          12,23-25
         </a>
         ]. In a study of 1180 surgical patients, those randomly assigned to receive potent inhalation anesthesia with
         <a class="drug drug_general" data-topicid="8992" href="/z/d/drug information/8992.html" rel="external">
          isoflurane
         </a>
         , enflurane, or
         <a class="drug drug_general" data-topicid="9887" href="/z/d/drug information/9887.html" rel="external">
          sevoflurane
         </a>
         had a higher risk of PONV compared with
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         , which has antiemetic properties (OR 2.4, 2.3, and 2.3, respectively) [
         <a href="#rid23">
          23
         </a>
         ] (see
         <a class="local">
          'Propofol'
         </a>
         below). The degree of risk was similar for each of the volatile anesthetics, was dose-related (ie, based on the duration of anesthesia), and was limited to the early postoperative period.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The use of total intravenous anesthesia (TIVA) rather than volatile anesthetics may also reduce hospital length of stay for patients or procedures that are at high risk for PONV or surgical complications related to vomiting. In a single institution retrospective cohort study of 448 patients who underwent laparoscopic Nissen fundoplication, the use of TIVA was associated with reduced hospital length of stay (OR for hospital length of stay ≤1 night 2.91 [95% CI 1.47-5.78]) and 7.8 percent reduction in cost of care [
         <a href="#rid26">
          26
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Another meta-analysis of 57 trials in adults and 13 trials in children found that
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         anesthesia resulted in 3.5-fold reduction of PONV in adults and 5.7-fold reduction in children [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Intravenous (IV) anesthetics
         </strong>
         –
         <strong>
         </strong>
         <a class="drug drug_general" data-topicid="8428" href="/z/d/drug information/8428.html" rel="external">
          Etomidate
         </a>
         does not independently increase PONV at doses commonly administered for induction of anesthesia [
         <a href="#rid28">
          28
         </a>
         ].
         <strong>
         </strong>
         Perioperative low-dose
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         may reduce PONV [
         <a href="#rid29">
          29
         </a>
         ] along with decreasing postoperative pain and opioid requirements [
         <a href="#rid29">
          29-31
         </a>
         ].
         <strong>
         </strong>
         There is lack of evidence to suggest an increase in PONV after an induction dose of ketamine (ie, 1 to 2 mg/kg IV) [
         <a href="#rid32">
          32
         </a>
         ]. Use of ketamine for perioperative analgesia is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/133187.html" rel="external">
          "Nonopioid pharmacotherapy for acute pain in adults", section on 'Ketamine'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Nitrous oxide
         </strong>
         <strong>
          (N
         </strong>
         <strong>
          <sub>
           2
          </sub>
         </strong>
         <strong>
          O)
         </strong>
         –
         <strong>
         </strong>
         N
         <sub>
          2
         </sub>
         O may modestly increase the risk of PONV, especially in high-risk adults and children, compared with N
         <sub>
          2
         </sub>
         O-free anesthesia [
         <a href="#rid25">
          25
         </a>
         ]. Studies of the emetogenic effect of N
         <sub>
          2
         </sub>
         O have been conflicting, with some reporting an increase in PONV with N
         <sub>
          2
         </sub>
         O [
         <a href="#rid33">
          33-35
         </a>
         ], and others reporting no effect [
         <a href="#rid36">
          36-38
         </a>
         ]. A meta-analysis of 30 studies including approximately 4600 patients reported a modestly-higher incidence of PONV with N
         <sub>
          2
         </sub>
         O compared with N
         <sub>
          2
         </sub>
         O-free anesthesia (33 versus 27 percent) [
         <a href="#rid24">
          24
         </a>
         ]. The maximal risk reduction with avoidance of N
         <sub>
          2
         </sub>
         O was in women (OR 0.7), and the difference between groups was eliminated by administration of a
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         infusion. In one subsequent study of 100 women who underwent laparoscopic-assisted hysterectomy, there was no difference in PONV in patients who were randomly assigned to have 70 percent N
         <sub>
          2
         </sub>
         O versus air added during the last 30 minutes of
         <a class="drug drug_general" data-topicid="8992" href="/z/d/drug information/8992.html" rel="external">
          isoflurane
         </a>
         anesthesia [
         <a href="#rid39">
          39
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Duration of anesthesia
         </strong>
         – Longer duration of anesthesia with volatile anesthetics may increase the risk of PONV [
         <a href="#rid14">
          14,15,40,41
         </a>
         ]. In addition to the increase in dose of anesthetics, longer procedures tend to be more invasive, and tend to require administration of larger doses of postoperative opioids than shorter procedures.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The emetogenic effect of N
         <sub>
          2
         </sub>
         O may depend on the duration of exposure as well. A meta-analysis of 29 randomized trials involving 10,317 patients found an insignificant risk of PONV from administration of N
         <sub>
          2
         </sub>
         O for less than one hour [
         <a href="#rid42">
          42
         </a>
         ]. After 45 minutes of administration, N
         <sub>
          2
         </sub>
         O increased the risk of PONV by 20 percent per hour. Conclusions from this study are limited by the possible effects of other anesthetics and/or the surgical procedure itself.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In children, surgery &gt;30 minutes increases the risk of POV compared with shorter procedures [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Opioid administration and reduction
         </strong>
         –
         <strong>
         </strong>
         Multiple studies have shown that administration of perioperative opioids increases the incidence of PONV [
         <a href="#rid11">
          11,12,14
         </a>
         ] in a dose-related manner [
         <a href="#rid43">
          43
         </a>
         ]. Multimodal perioperative pain control strategies that reduce or eliminate opioid administration reduce the incidence of PONV [
         <a href="#rid44">
          44-48
         </a>
         ]. In children, administration of
         <a class="drug drug_general" data-topicid="8897" href="/z/d/drug information/8897.html" rel="external">
          dexmedetomidine
         </a>
         may be particularly beneficial for its opioid-sparing effects and to reduce the incidence of emergence delirium. (See
         <a class="medical medical_review" href="/z/d/html/94564.html" rel="external">
          "Emergence delirium and agitation in children", section on 'Prevention'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/130312.html" rel="external">
          "Approach to the management of acute pain in adults", section on 'Use multimodal analgesia'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Sugammadex
         </strong>
         <strong>
          versus
         </strong>
         <strong>
          neostigmine
         </strong>
         <strong>
          for reversal of neuromuscular blockade
         </strong>
         –
         <strong>
         </strong>
         We do not choose the reversal for neuromuscular blocking agents based on a possible effect on PONV. Contrary to popular belief, IV
         <a class="drug drug_general" data-topicid="9693" href="/z/d/drug information/9693.html" rel="external">
          neostigmine
         </a>
         for reversal of neuromuscular block does not appear to significantly increase the risk of PONV. A meta-analysis of 10 randomized trials including 933 patients reported that the combination of neostigmine with either
         <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">
          atropine
         </a>
         or
         <a class="drug drug_general" data-topicid="8496" href="/z/d/drug information/8496.html" rel="external">
          glycopyrrolate
         </a>
         did not significantly increase the incidence of overall nausea (relative risk [RR] 1.24) or vomiting (RR 0.91) [
         <a href="#rid49">
          49
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         There are limited data on the incidence of PONV after reversal of neuromuscular blocking agents with
         <a class="drug drug_general" data-topicid="105866" href="/z/d/drug information/105866.html" rel="external">
          sugammadex
         </a>
         . In one study of approximately 100 patients who were randomly assigned to reversal with
         <a class="drug drug_general" data-topicid="9693" href="/z/d/drug information/9693.html" rel="external">
          neostigmine
         </a>
         or sugammadex, the incidence of nausea and/or vomiting in the first postoperative hour was lower after sugammadex, but PONV over the first 24 hours was similar with the two drugs [
         <a href="#rid50">
          50
         </a>
         ]. A systematic review and meta-analysis of six studies found that the PONV risk was decreased when sugammadex was used instead of neostigmine for the reversal of neuromuscular blockade, with the number needed to treat to prevent PONV cited at 16 [
         <a href="#rid51">
          51
         </a>
         ]. However, conclusions from this study are limited by unclear baseline risk of PONV of study subjects and inclusion of open label studies.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2012868701">
         <span class="h2">
          Type of surgery
         </span>
         <span class="headingEndMark">
          —
         </span>
         Studies of the effect of the type of surgery on the incidence of PONV have reported conflicting results. The best evidence suggests that cholecystectomy, gynecologic, and laparoscopic procedures are associated with modestly increased risk of PONV compared with other general surgical procedures [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p>
         In children, strabismus surgery is an independent, and possibly the most significant, predictor for POV [
         <a href="#rid13">
          13,16,52
         </a>
         ]. In addition, POV occurs in as many as 70 percent of children without prophylaxis who undergo adenotonsillectomy [
         <a href="#rid53">
          53
         </a>
         ], up to 60 percent of children who undergo otoplasty [
         <a href="#rid54">
          54
         </a>
         ], and 40 percent of those who undergo inguinal scrotal or penile procedures [
         <a href="#rid55">
          55
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H435405590">
         <span class="h2">
          Risk scores
         </span>
         <span class="headingEndMark">
          —
         </span>
         A number of predictive models, or scoring systems, have been developed to stratify the risk of PONV, based on patient, anesthetic, and surgical risk factors. The score may be used to determine the appropriate degree of intervention for prophylaxis  (
         <a class="graphic graphic_figure graphicRef86808" href="/z/d/graphic/86808.html" rel="external">
          figure 2
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H440882333">
         <span class="h3">
          Risk score for postoperative nausea and vomiting for adults
         </span>
         <span class="headingEndMark">
          —
         </span>
         We use the simplified risk score for PONV that was created by Apfel, et al [
         <a href="#rid11">
          11
         </a>
         ] to evaluate adults preoperatively, and base the preventive strategy on the resulting degree of predicted risk. The simplified risk score is easy to use and accurately predicts the risk for PONV in our adult patients. The components of the simplified risk score include the following four highly predictive risk factors:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Female gender
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Nonsmoker
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         History of motion sickness or previous PONV
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Expected administration of postoperative opioids
        </p>
        <p>
        </p>
        <p>
         This risk score has been validated within and across institutions; the presence of 0, 1, 2, 3, and 4 of these risk factors corresponds to risk of PONV of 10, 20, 40, 60, and 80 percent, respectively [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2088878686">
         <span class="h3">
          Risk score for postoperative vomiting for children
         </span>
         <span class="headingEndMark">
          —
         </span>
         The risk scores used for adult patients are not applicable for children [
         <a href="#rid17">
          17
         </a>
         ]. We use a scoring system that includes preoperative, intraoperative, and postoperative risk factors, which appears in the 2020 Fourth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting from the American Society of Enhanced Recovery and the Society for Ambulatory Anesthesia [
         <a href="#rid56">
          56
         </a>
         ]. Those risk factors are shown in a table  (
         <a class="graphic graphic_table graphicRef130337" href="/z/d/graphic/130337.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H1226576483">
         <span class="h1">
          PREVENTION
         </span>
        </p>
        <p class="headingAnchor" id="H2659650314">
         <span class="h2">
          Our strategy
         </span>
         <span class="headingEndMark">
          —
         </span>
         The management strategy for PONV should include risk assessment (including patient and surgical factors), an emphasis on multimodal preventive measures based on the risk assessment, and evidenced-based interventions when PONV occurs. Our approach is generally consistent with the 2020 Fourth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting from the American Society of Enhanced Recovery and the Society for Ambulatory Anesthesia [
         <a href="#rid56">
          56
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H620505717">
         <span class="h3">
          Preventive measures for all patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         We employ a multimodal, opioid-sparing or opioid-free strategy for effective perioperative pain control; the reduction of pain has been correlated with a reduction in PONV [
         <a href="#rid57">
          57
         </a>
         ]. Additional preventive measures may include modification of anesthetic technique and medications used, administration of antiemetics, and use of nonpharmacologic measures for prophylaxis. (See
         <a class="medical medical_review" href="/z/d/html/127173.html" rel="external">
          "Approach to the management of acute perioperative pain in infants and children", section on 'Opioid avoidance'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/130312.html" rel="external">
          "Approach to the management of acute pain in adults", section on 'Minimize opioids'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1157266081">
         <span class="h3">
          Risk stratification
         </span>
         <span class="headingEndMark">
          —
         </span>
         The decision to administer prophylaxis for PONV should be made with the following factors in mind:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The patient-specific risk of PONV (ie, the number of risk factors for PONV)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The consequences of nausea and vomiting related to the surgical procedure (eg, wound disruption, increase in intracranial pressure, clot disruption after angiographic procedures)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patient and clinician preferences
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Implications for a change in routine anesthetic technique (eg, using total intravenous anesthesia [TIVA] in pediatric patients, who would otherwise receive
         <a class="drug drug_general" data-topicid="9887" href="/z/d/drug information/9887.html" rel="external">
          sevoflurane
         </a>
         anesthesia)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3086863818">
         <span class="h2">
          Prophylaxis based on risk
         </span>
         <span class="headingEndMark">
          —
         </span>
         We recommend prophylaxis for PONV for all patients who have risk factors for PONV, rather than no prophylaxis. We suggest multimodal prophylaxis, with antiemetics from different drug classes, and possibly modification of the anesthetic.
        </p>
        <p class="headingAnchor" id="H423076858">
         <span class="h3">
          Adults
         </span>
         <span class="headingEndMark">
          —
         </span>
         Our approach to prophylaxis for PONV in adults is shown in an algorithm  (
         <a class="graphic graphic_algorithm graphicRef111057" href="/z/d/graphic/111057.html" rel="external">
          algorithm 1
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H3330082503">
         <span class="h4">
          Adults with ≥3 risk factors
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with three or four risk factors, we use three or more interventions, including at least three antiemetics from different drug classes, and may also use
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         anesthesia, and/or acupuncture [
         <a href="#rid56">
          56,58
         </a>
         ]. (See
         <a class="local">
          'Risk score for postoperative nausea and vomiting for adults'
         </a>
         above.)
        </p>
        <p>
         In our hospital-based practice of both ambulatory and inpatient surgeries where we have a limited hospital-based drug formulary, our strategy for PONV prophylaxis for high-risk adults is described here. The efficacy of specific interventions is detailed below. (See
         <a class="local">
          'Options for prophylaxis in adults and children'
         </a>
         below.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Anesthetic technique
         </strong>
         –
         <strong>
         </strong>
         We offer regional anesthesia rather than general anesthesia if appropriate for the surgery. If general anesthesia is required, we prefer TIVA with
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         and opioid-sparing anesthetic techniques.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Antiemetics
         </strong>
         –
         <strong>
         </strong>
         We usually administer the following antiemetics:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Scopolamine
         </strong>
         <strong>
          patch
         </strong>
         – We have the patient apply a
         <a class="drug drug_general" data-topicid="9915" href="/z/d/drug information/9915.html" rel="external">
          scopolamine
         </a>
         patch at least two hours prior to the induction of anesthesia, with instructions to remove the patch within 24 hours after surgery. If necessary, we apply the patch preoperatively. (See
         <a class="local">
          'Anticholinergics'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Dexamethasone
         </strong>
         – 4 to 8 mg intravenously (IV) after induction. (See
         <a class="local">
          'Glucocorticoids'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Ondansetron
         </strong>
         – 4 mg IV at the end of surgery. (See
         <a class="local">
          'Serotonin (5-hydroxytryptamine) receptor antagonists'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients who do not receive a
         <a class="drug drug_general" data-topicid="9915" href="/z/d/drug information/9915.html" rel="external">
          scopolamine
         </a>
         patch (eg, patients with angle closure glaucoma), we administer
         <a class="drug drug_general" data-topicid="8896" href="/z/d/drug information/8896.html" rel="external">
          dimenhydrinate
         </a>
         25 to 50 mg IV,
         <a class="drug drug_general" data-topicid="9816" href="/z/d/drug information/9816.html" rel="external">
          prochlorperazine
         </a>
         5 to 10 mg IV, or
         <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">
          haloperidol
         </a>
         1 mg IV, as a third antiemetic. (See
         <a class="local">
          'Antihistamines'
         </a>
         below and
         <a class="local">
          'Phenothiazines'
         </a>
         below and
         <a class="local">
          'Antidopaminergics'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Rescue antiemetics
         </strong>
         – If nausea and vomiting occur in the post-anesthesia care unit (PACU), we administer an antiemetic from a different class of drug from those used for prophylaxis. Our usual options include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="9816" href="/z/d/drug information/9816.html" rel="external">
          Prochlorperazine
         </a>
         5 to 10 mg IV (see
         <a class="local">
          'Phenothiazines'
         </a>
         below), or
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="9395" href="/z/d/drug information/9395.html" rel="external">
          Droperidol
         </a>
         0.625 mg IV (see
         <a class="local">
          'Antidopaminergics'
         </a>
         below)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2609076195">
         <span class="h4">
          Adults with one or two risk factors
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with one or two risk factors for PONV (including patients with any risk factor for PONV and patients who receive inhalation anesthesia or TIVA that includes opioids), we use two or more interventions. We administer two antiemetics of different drug classes, and may also choose to either modify the anesthetic technique (ie, regional anesthesia or TIVA with
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         ) or perform acupuncture. (See
         <a class="local">
          'Reduction of baseline risk'
         </a>
         below and
         <a class="local">
          'Antiemetics'
         </a>
         below and
         <a class="local">
          'Nonpharmacologic techniques'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H431549666">
         <span class="h4">
          Adults without risk factors
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For adults without preoperative risk factors for PONV who receive inhalation anesthesia or TIVA that includes opioids, we usually administer
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         4 to 8 mg IV after induction of anesthesia, and also
         <a class="drug drug_general" data-topicid="9719" href="/z/d/drug information/9719.html" rel="external">
          ondansetron
         </a>
         4 mg IV at the end of surgery.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For adults without preoperative risk factors who receive regional anesthesia or TIVA with
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         without intraoperative or postoperative opioid, we do not usually administer PONV prophylaxis, though others do. (See
         <a class="local">
          'Antiemetics'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2246381758">
         <span class="h3">
          Children
         </span>
         <span class="headingEndMark">
          —
         </span>
         Ours is a hospital-based practice of both ambulatory and inpatient surgeries where we have a limited hospital-based drug formulary. Our approach to PONV in children is shown in an algorithm  (
         <a class="graphic graphic_algorithm graphicRef130341" href="/z/d/graphic/130341.html" rel="external">
          algorithm 2
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H2720845027">
         <span class="h4">
          Children with ≥3 risk factors
         </span>
         <span class="headingEndMark">
          —
         </span>
         For high-risk children (ie, with ≥3 risk factors), our strategy is as follows (see
         <a class="local">
          'Risk score for postoperative vomiting for children'
         </a>
         above):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Anesthetic technique
         </strong>
         – We offer regional anesthesia with sedation to older children. If general anesthesia is required, as it is in most children, we prefer TIVA with
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         for very-high-risk patients.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Antiemetics
         </strong>
         – We administer the following antiemetics:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          Dexamethasone
         </a>
         0.25 mg/kg IV, maximum 4 mg (see
         <a class="local">
          'Glucocorticoids'
         </a>
         below)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="9719" href="/z/d/drug information/9719.html" rel="external">
          Ondansetron
         </a>
         0.1 mg/kg IV, maximum 4 mg (see
         <a class="local">
          'Serotonin (5-hydroxytryptamine) receptor antagonists'
         </a>
         below)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Rescue antiemetics
         </strong>
         –
         <strong>
         </strong>
         For POV rescue, our usual choices include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="8896" href="/z/d/drug information/8896.html" rel="external">
          Dimenhydrinate
         </a>
         or
         <a class="drug drug_general" data-topicid="9369" href="/z/d/drug information/9369.html" rel="external">
          diphenhydramine
         </a>
         0.5 mg/kg IV, maximum 25 mg (see
         <a class="local">
          'Antihistamines'
         </a>
         below)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="9719" href="/z/d/drug information/9719.html" rel="external">
          Ondansetron
         </a>
         , repeat dose 0.1 mg/kg IV, maximum 4 mg, total perioperative maximum 8 mg (see
         <a class="local">
          'Serotonin (5-hydroxytryptamine) receptor antagonists'
         </a>
         below)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2560050271">
         <span class="h4">
          Children with one or two risk factors
         </span>
         <span class="headingEndMark">
          —
         </span>
         We manage moderate-risk children (ie, those with one or two risk factors) as we would high-risk children, as described above, without using TIVA. (See
         <a class="local">
          'Risk score for postoperative vomiting for children'
         </a>
         above and
         <a class="local">
          'Children with ≥3 risk factors'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H3213524084">
         <span class="h4">
          Children without risk factors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Prophylaxis for POV for children without risk factors should be based on clinician and patient preferences, formulary choices, and cost, and may include zero or one prophylactic intervention. For children with no risk factors for POV, we administer
         <a class="drug drug_general" data-topicid="9719" href="/z/d/drug information/9719.html" rel="external">
          ondansetron
         </a>
         0.1 mg/kg IV, maximum 4 mg. For rescue antiemetic, we administer
         <a class="drug drug_general" data-topicid="8896" href="/z/d/drug information/8896.html" rel="external">
          dimenhydrinate
         </a>
         or
         <a class="drug drug_general" data-topicid="9369" href="/z/d/drug information/9369.html" rel="external">
          diphenhydramine
         </a>
         0.5 mg/kg IV, maximum 25 mg, or ondansetron, repeat dose 0.1 mg/kg IV, maximum 4 mg, total perioperative maximum 8 mg.
        </p>
        <p class="headingAnchor" id="H2892527150">
         <span class="h2">
          Options for prophylaxis in adults and children
         </span>
         <span class="headingEndMark">
          —
         </span>
         All patients should receive a multimodal, opioid-sparing approach for effective postoperative pain control  (
         <a class="graphic graphic_algorithm graphicRef111057" href="/z/d/graphic/111057.html" rel="external">
          algorithm 1
         </a>
         and
         <a class="graphic graphic_algorithm graphicRef130341" href="/z/d/graphic/130341.html" rel="external">
          algorithm 2
         </a>
         ). (See
         <a class="local">
          'Reduction of baseline risk'
         </a>
         below and
         <a class="local">
          'Antiemetics'
         </a>
         below and
         <a class="local">
          'Nonpharmacologic techniques'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1499538518">
         <span class="h3">
          Reduction of baseline risk
         </span>
         <span class="headingEndMark">
          —
         </span>
         The baseline risk of PONV and POV may be reduced as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Modification of anesthetic technique
         </strong>
         (see
         <a class="local">
          'Anesthetic factors'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Use of regional anesthesia rather than general anesthesia
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Use of TIVA with
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         , rather than volatile anesthetics
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adequate hydration
         </strong>
         –
         <strong>
         </strong>
         In clinical practice, decisions regarding IV fluid administration in adults are usually based on factors other than the risk of PONV. The literature on the effect of the type and amount of IV fluid on PONV in adults is conflicting. A meta-analysis of 15 randomized trials including approximately 1600 patients found that liberal intraoperative crystalloid administration (15 to 30 mL/kg) reduced the risk of late and overall PONV but not early PONV compared with restrictive IV fluids (0 to 2 mL/kg) [
         <a href="#rid59">
          59
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A 2019 meta-analysis of 41 randomized trials including approximately 4200 healthy patients who underwent general anesthesia for ambulatory or short stay surgery found that administration of at least 10 mL/kg IV crystalloid was associated with reduced risk of PONV and reduced requirement for treatment for PONV, compared with lower volume crystalloid [
         <a href="#rid60">
          60
         </a>
         ]. However, the quality of evidence was moderate, with heterogeneous methods and volumes of IV fluid administration, and unclear risk of bias. Risk of serious adverse events and unanticipated postoperative hospital admission related to vigorous IV crystalloid administration were not reported.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Liberal fluid administration may be beneficial in children for prevention of PONV. In a meta-analysis of seven small randomized trials of children who underwent surgery with volatile anesthetics without PONV prophylaxis, administration of supplemental IV fluid (20 or 30 mL/kg/hour) reduced PONV compared with more conservative IV fluid administration at 10 mL/kg/hour (25 versus 50 percent) [
         <a href="#rid61">
          61
         </a>
         ]. In our practice, we consider administration of liberal amounts of IV fluid for children who have had POV despite multiple preventive strategies with prior anesthetics, unless the child is undergoing bowel or bariatric surgery. Similar to adults, restrictive or goal-directed fluid management is increasingly used for children who undergo these procedures [
         <a href="#rid62">
          62
         </a>
         ]. Intraoperative fluid management is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/14942.html" rel="external">
          "Intraoperative fluid management"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8711" href="/z/d/drug information/8711.html" rel="external">
          Intravenous dextrose
         </a>
         <strong>
          solution
         </strong>
         –
         <strong>
         </strong>
         Studies of the effect of perioperative administration of IV dextrose solutions on PONV have reported mixed results. A 2019 meta-analysis of 10 randomized trials including approximately 1000 patients who underwent a variety of surgical procedures round that use of an IV dextrose infusion was not associated with a reduction in nausea and vomiting in the postanesthesia care unit (PACU) or in the first 24 hours after surgery [
         <a href="#rid63">
          63
         </a>
         ]. In a 2020 meta-analysis of 11 trials of almost exclusively female patients, perioperative dextrose administration slightly reduced the incidence of early and postoperative nausea, without an effect on vomiting [
         <a href="#rid64">
          64
         </a>
         ]. Overall quality of evidence was rated low.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Intraoperative administration of
         <a class="drug drug_general" data-topicid="8711" href="/z/d/drug information/8711.html" rel="external">
          IV dextrose
         </a>
         solutions can cause hyperglycemia, even in nondiabetic patients [
         <a href="#rid65">
          65
         </a>
         ]. In one study of dextrose administration for PONV prevention in nondiabetic patients who underwent laparoscopic cholecystectomy, mean blood glucose after the infusion of 5% dextrose was 282 mg/dL, versus 92 mg/dL after infusion of Ringer's lactate [
         <a href="#rid66">
          66
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Multimodal postoperative pain control
         </strong>
         –
         <strong>
         </strong>
         A multimodal strategy for perioperative pain control including regional anesthesia techniques, nonopioid analgesics, other nonopioid adjuvants, and nonpharmacologic therapies, may reduce the need for postoperative opioids and the risk of PONV and POV. (See
         <a class="local">
          'Anesthetic factors'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/130312.html" rel="external">
          "Approach to the management of acute pain in adults", section on 'Use multimodal analgesia'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H144014180">
         <span class="h3">
          Antiemetics
         </span>
         <span class="headingEndMark">
          —
         </span>
         A variety of antiemetics acting via different mechanisms are used for prevention and treatment of PONV. In general, clinicians choose among these agents based upon side effect profile, personal experience, cost, and formulary considerations  (
         <a class="graphic graphic_table graphicRef65891" href="/z/d/graphic/65891.html" rel="external">
          table 2
         </a>
         and
         <a class="graphic graphic_table graphicRef130338" href="/z/d/graphic/130338.html" rel="external">
          table 3
         </a>
         ). Side effects of many of these agents when used for PONV prophylaxis have not been well studied [
         <a href="#rid67">
          67
         </a>
         ]; where appropriate they are mentioned in descriptions of drugs below.
        </p>
        <p>
         The mechanisms of action of antiemetics are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2538.html" rel="external">
          "Characteristics of antiemetic drugs"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2430614242">
         <span class="h4">
          General principles
         </span>
         <span class="headingEndMark">
          —
         </span>
         The following principles apply to the use of antiemetics in this setting:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Commonly used antiemetics reduce the risk of PONV by approximately 25 percent  (
         <a class="graphic graphic_table graphicRef65891" href="/z/d/graphic/65891.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid68">
          68
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The absolute benefit of an antiemetic depends on the degree of baseline risk, with higher-risk patients benefiting more than low-risk patients [
         <a href="#rid68">
          68
         </a>
         ]. As examples, for a patient with a baseline risk of PONV of 80 percent (eg, a female nonsmoker with a history of motion sickness who requires postoperative opioids),
         <a class="drug drug_general" data-topicid="9719" href="/z/d/drug information/9719.html" rel="external">
          ondansetron
         </a>
         would reduce the risk of PONV by approximately 20 percent to a risk of 60 percent. By contrast, for a patient with baseline risk of 10 percent (eg, a male smoker without motion sickness who does not require postoperative opioids), ondansetron would reduce the risk of PONV by only 2.5 percent, to a risk of 7.5 percent.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The effects of drugs that act on different receptors are additive rather than synergistic. Because each drug reduces PONV by a fraction of the existing risk, each added drug results in less antiemetic benefit [
         <a href="#rid68">
          68
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The antiemetic benefit from TIVA with
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         is approximately the same as administration of one antiemetic with volatile inhalation anesthesia [
         <a href="#rid68">
          68
         </a>
         ]. There is further risk reduction of PONV when TIVA with propofol is used with another TIVA agent (ie,
         <a class="drug drug_general" data-topicid="8897" href="/z/d/drug information/8897.html" rel="external">
          dexmedetomidine
         </a>
         for opioid sparing effect) [
         <a href="#rid69">
          69
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         All antiemetics have side effects, some more serious than others (eg, headache, sedation, electrocardiogram [ECG] QT interval prolongation).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Rescue treatment should include an antiemetic from a different class than the drugs that were used for prophylaxis unless the effect of the previous drug has likely worn off.
        </p>
        <p>
        </p>
        <p>
         Commonly used antiemetics are described in the following sections  (
         <a class="graphic graphic_table graphicRef65891" href="/z/d/graphic/65891.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H3622478147">
         <span class="h4">
          Serotonin (5-hydroxytryptamine) receptor antagonists
         </span>
         <span class="headingEndMark">
          —
         </span>
         The 5-hydroxytryptamine type 3 (5-HT
         <sub>
          3
         </sub>
         ) receptor antagonists are commonly used for prevention and treatment of PONV. Their lack of sedative effects is an advantage in the postoperative period; some clinicians avoid the 5-HT
         <sub>
          3
         </sub>
         antagonists intraoperatively to save these drugs for possible rescue in the PACU.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          First-generation serotonin antagonists
         </strong>
         –
         <strong>
         </strong>
         The first-generation serotonin antagonists (ie,
         <a class="drug drug_general" data-topicid="9719" href="/z/d/drug information/9719.html" rel="external">
          ondansetron
         </a>
         ,
         <a class="drug drug_general" data-topicid="8501" href="/z/d/drug information/8501.html" rel="external">
          granisetron
         </a>
         ,
         <a class="drug drug_general" data-topicid="8592" href="/z/d/drug information/8592.html" rel="external">
          dolasetron
         </a>
         , and, outside the United States, tropisetron) are equally efficacious for PONV at equipotent doses (relative risk [RR] 0.76 versus placebo) [
         <a href="#rid70">
          70
         </a>
         ]. Ondansetron may be the most commonly used antiemetic in this class, given its low cost and benign side effect profile. All of these drugs have potential to prolong the electrocardiogram intervals, particularly the QT interval, and should be avoided for patients at risk for QTc prolongation (ie, patients with congenital long QT syndrome, congestive heart failure, bradyarrhythmias, or patients who are already taking medications that prolong the QT interval) [
         <a href="#rid71">
          71
         </a>
         ]. In 2021, the US Food and Drug Administration (FDA) mandated a
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2021%2F020103s038%2C020605s022%2C020781s022lbl.pdf&amp;token=dXVV3%2FfVvvaaJ309XH0CIfyQuNPu%2BhXf8kB0Vavxt8VRJhVZnKs4sRW9Oi4uOPkgVksNgsn4uIQs2UlQmx4HbQImUNsKGgIDvmFX2YNUa5FfOx2CFj90px1g485CxhZ%2F&amp;TOPIC_ID=16849" target="_blank">
          label change
         </a>
         for ondansetron to include a warning that there have been reported cases of myocardial ischemia after administration of the drug. The incidence is likely extremely rare, since there have been very few reported cases and ondansetron is very commonly used. A causal link has not been definitively established. Coronary spasm has been proposed as a possible etiology.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         These agents are administered as a single dose IV at the end of surgery.
         <a class="drug drug_general" data-topicid="9719" href="/z/d/drug information/9719.html" rel="external">
          Ondansetron
         </a>
         is available as an orally disintegrating film (ODF) and as an orally disintegrating tablet (ODT), both of which are administered at twice the IV dose. Oral preparations are as effective as IV ondansetron, administered 30 to 60 minutes prior to surgery [
         <a href="#rid72">
          72,73
         </a>
         ]. The ODT may be useful for postdischarge administration and may be administered to children over the age of five [
         <a href="#rid74">
          74
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Ondansetron
         </strong>
         – Adults 4 mg IV or 8 mg orally prior to surgery [
         <a href="#rid68">
          68,75-77
         </a>
         ], children 0.1 mg/kg IV, maximum 4 mg [
         <a href="#rid78">
          78
         </a>
         ].
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Granisetron
         </strong>
         – Adults 0.35 to 3 mg IV [
         <a href="#rid79">
          79,80
         </a>
         ], children 40 mcg/kg IV, maximum 0.6 mg [
         <a href="#rid81">
          81
         </a>
         ].
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Dolasetron
         </strong>
         – Adults 12.5 mg IV [
         <a href="#rid82">
          82
         </a>
         ], children 0.35 mg/kg IV, maximum 12.5 mg.
         <a class="drug drug_general" data-topicid="8592" href="/z/d/drug information/8592.html" rel="external">
          Dolasetron
         </a>
         is contraindicated at the high doses previously used for prevention of chemotherapy-induced nausea and vomiting (CINV), due to the risk of QTc prolongation and fatal torsade de pointes at those doses [
         <a href="#rid83">
          83
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1151.html" rel="external">
          "Prevention of chemotherapy-induced nausea and vomiting in adults", section on 'Dolasetron'
         </a>
         .)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Tropisetron
         </strong>
         – Adults 2 mg IV at the end surgery [
         <a href="#rid84">
          84
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Second-generation serotonin antagonist
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Palonosetron
         </strong>
         <strong>
         </strong>
         –
         <strong>
         </strong>
         <a class="drug drug_general" data-topicid="9944" href="/z/d/drug information/9944.html" rel="external">
          Palonosetron
         </a>
         is a second-generation serotonin antagonist. Compared with the first-generation drugs in this class, palonosetron has unique and higher receptor binding affinity [
         <a href="#rid85">
          85
         </a>
         ], and a longer half-life of 40 hours [
         <a href="#rid86">
          86
         </a>
         ], with similar efficacy for prevention of PONV [
         <a href="#rid87">
          87,88
         </a>
         ]. Because of its prolonged action, palonosetron may be particularly effective for prevention of late or postdischarge nausea and vomiting (PDNV). (See
         <a class="local">
          'Postdischarge nausea and vomiting'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <a class="drug drug_general" data-topicid="9944" href="/z/d/drug information/9944.html" rel="external">
          Palonosetron
         </a>
         does not appear to affect the QT interval. Palonosetron 0.075 mg is more efficacious at preventing PONV compared with
         <a class="drug drug_general" data-topicid="9719" href="/z/d/drug information/9719.html" rel="external">
          ondansetron
         </a>
         4 and 8 mg,
         <a class="drug drug_general" data-topicid="8501" href="/z/d/drug information/8501.html" rel="external">
          granisetron
         </a>
         1 mg,
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         5 and 8 mg, tropisetron 2 mg, and ramosetron 0.3 mg [
         <a href="#rid89">
          89-91
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Palonosetron
         </strong>
         <strong>
          dose
         </strong>
         – Adults 0.075 mg IV [
         <a href="#rid87">
          87
         </a>
         ] at induction of anesthesia, children 0.5 to 1.5 mcg/kg IV [
         <a href="#rid92">
          92,93
         </a>
         ] (limited data)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Ramosetron
         </strong>
         – Ramosetron is a second generation 5 hydroxytryptamine type 3 (5HT-3; serotonin) receptor antagonist, not licensed for use in the United States. Elsewhere, ramosetron is approved for the treatment of chemotherapy induced nausea and vomiting. (See
         <a class="medical medical_review" href="/z/d/html/1151.html" rel="external">
          "Prevention of chemotherapy-induced nausea and vomiting in adults", section on 'First-generation agents'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Ramosetron
         </strong>
         <strong>
          dose
         </strong>
         – Adults 0.3 to 0.6 mg IV at the end of surgery [
         <a href="#rid94">
          94,95
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H72946217">
         <span class="h4">
          Glucocorticoids
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          Dexamethasone
         </a>
         is as effective as
         <a class="drug drug_general" data-topicid="9719" href="/z/d/drug information/9719.html" rel="external">
          ondansetron
         </a>
         and
         <a class="drug drug_general" data-topicid="9395" href="/z/d/drug information/9395.html" rel="external">
          droperidol
         </a>
         for prevention of PONV (RR 0.76 versus placebo) [
         <a href="#rid68">
          68,96,97
         </a>
         ], and is the most commonly used and studied corticosteroid for POV prophylaxis in children [
         <a href="#rid98">
          98
         </a>
         ].
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          Dexamethasone
         </a>
         may be beneficial because of a direct antiemetic effect and by reducing postoperative pain and the need for postoperative opioids. Lower doses of dexamethasone may be required for PONV prophylaxis than for pain relief. A meta-analysis of 60 randomized trials with 6700 patients found that a dose of 4 to 5 mg IV dexamethasone was as effective as 8 to 10 mg IV for reduction of PONV [
         <a href="#rid99">
          99
         </a>
         ]. In contrast, two meta-analyses of studies comparing lower-dose (&lt;0.1 mg/kg IV) dexamethasone with higher doses (&gt;0.1 mg/kg) found that higher doses were required for reduced opioid requirement [
         <a href="#rid100">
          100,101
         </a>
         ]. A subsequent multicenter randomized trial including 1350 patients who underwent bowel surgery reported that a single postinduction dose of dexamethasone 8 mg IV reduced the incidence of PONV at 24 hours and the need for rescue antiemetic for up to 72 hours [
         <a href="#rid102">
          102
         </a>
         ]. In the randomized international trial described below (PADDI), dexamethasone 8 mg IV reduced PONV in the first 24 hours after surgery (42.2 versus 53.9 percent, risk ratio 0.78; 95% CI 0.75–0.82) [
         <a href="#rid103">
          103
         </a>
         ]. In a substudy of 1466 patients in the PADDI trial, dexamethasone reduced the incidence and severity of PONV on days one and two postoperatively [
         <a href="#rid104">
          104
         </a>
         ]. Conclusions from this study are limited by the small number of PONV events.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Safety of
         </strong>
         <strong>
          dexamethasone
         </strong>
         <strong>
         </strong>
         – Data on the safety of prophylactic
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         are inconclusive, and the use of dexamethasone should be individualized. (See
         <a class="medical medical_review" href="/z/d/html/94216.html" rel="external">
          "Anesthesia for tonsillectomy with or without adenoidectomy in children", section on 'Dexamethasone'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Surgical site infection
         </strong>
         – Most studies have shown no increase in wound infection with one dose of
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         [
         <a href="#rid105">
          105-109
         </a>
         ]. In a randomized multicenter international noninferiority trial (PADDI) including approximately 8700 patients who had general anesthesia for noncardiac surgery, the incidence of surgical site infection within 30 days of surgery was similar in patients who received dexamethasone 8 mg IV during surgery versus those who received placebo (8.1 versus 9.1 percent) [
         <a href="#rid103">
          103
         </a>
         ]. The results were similar in patients with and without diabetes, and across types of infection (ie, superficial, deep, organ space).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Increase in blood glucose
         </strong>
         –
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          Dexamethasone
         </a>
         at the doses used for PONV prophylaxis (ie, up to 8 mg IV) can cause a modest glucose elevation in patients with or without diabetes, over and above the typical increase in glucose that occurs as a result of surgery [
         <a href="#rid109">
          109-112
         </a>
         ]. The increase in glucose after dexamethasone administration may be greater in patients without diabetes [
         <a href="#rid113">
          113
         </a>
         ], and in patients with diabetes the increase may depend on the degree of control of diabetes [
         <a href="#rid114">
          114
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         In a meta-analysis of 56 randomized trials that evaluated glucocorticoid administration in patients who had elective surgery, the mean increase in perioperative glucose concentration was 20 mg/dL (95% CI 11.4–28.6) [
         <a href="#rid108">
          108
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         In the large international trial described above, the median difference between preoperative and peak blood glucose in patients who received
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         was 65 mg/dL compared with a median increase of 43 mg/dL in patients who received placebo [
         <a href="#rid103">
          103
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         In one trial, 302 elective noncardiac surgical patients were randomly assigned to
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         4 or 8 mg or placebo, during surgery [
         <a href="#rid114">
          114
         </a>
         ]. Blood glucose increased in all groups. The increase was similar after 4 or 8 mg dexamethasone in patients without diabetes and patients with well controlled diabetes. In patients with high preoperative hemoglobin A1C, the increase was greater with an 8 mg dose, compared with a 4 mg dose of dexamethasone.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         In another trial, 185 patients (49 with diabetes) who had major noncardiac surgery were randomly assigned to receive 8 mg
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         IV during surgery versus placebo [
         <a href="#rid113">
          113
         </a>
         ]. Mean blood glucose increased in both groups; increase in blood glucose was greater in patients without diabetes than in those with diabetes (72 ± 45 versus 63 ± 69 mg/dL). In patients with diabetes, the increase in blood glucose was similar with dexamethasone versus placebo. In patients without diabetes, dexamethasone increased blood glucose by a mean of 29 mg/dL compared with placebo.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Concerns for patients with cancer
         </strong>
         – In pediatric oncology patients who undergo anesthesia for bone marrow biopsy or lumbar puncture, glucocorticoids can interfere with cell counts and, ultimately, chemotherapeutic management or, rarely, can cause tumor lysis syndrome [
         <a href="#rid58">
          58
         </a>
         ]. The patient's oncologist should be consulted prior to administration of
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         . (See
         <a class="medical medical_review" href="/z/d/html/1154.html" rel="external">
          "Tumor lysis syndrome: Pathogenesis, clinical manifestations, definition, etiology and risk factors"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dexamethasone
         </strong>
         <strong>
          dose
         </strong>
         —
         <strong>
         </strong>
         Because of its slow onset,
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         is more effective if administered after induction rather than at the end of surgery [
         <a href="#rid96">
          96
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Adults 4 mg to 8 mg IV [
         <a href="#rid115">
          115,116
         </a>
         ] after induction
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Children 0.25 mg/kg, maximum 4 mg [
         <a href="#rid117">
          117
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H316232496">
         <span class="h4">
          Anticholinergics
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9915" href="/z/d/drug information/9915.html" rel="external">
          Scopolamine
         </a>
         is an anticholinergic medication applied as a 1.5 mg transdermal preparation for PONV prophylaxis. Transdermal scopolamine (TDS) is a sustained-release, long-acting patch that is applied at least several hours prior to anesthesia, and is as effective as
         <a class="drug drug_general" data-topicid="9719" href="/z/d/drug information/9719.html" rel="external">
          ondansetron
         </a>
         and
         <a class="drug drug_general" data-topicid="9395" href="/z/d/drug information/9395.html" rel="external">
          droperidol
         </a>
         for PONV prophylaxis [
         <a href="#rid118">
          118
         </a>
         ]. A meta-analysis of 25 randomized trials with 3300 patients found that TDS was associated with a reduced risk of PONV (RR 0.73) compared with placebo during the first 24 hours after anesthesia [
         <a href="#rid119">
          119
         </a>
         ]. TDS was as effective if applied the evening prior to surgery as when applied two to four hours prior to anesthesia. The side effects of scopolamine are mild, and include dry mouth and blurry vision [
         <a href="#rid119">
          119,120
         </a>
         ]. Confusion or agitation may occur, especially in older adults with baseline cognitive impairment [
         <a href="#rid121">
          121,122
         </a>
         ]. Acute angle closure glaucoma is a possible side effect of scopolamine [
         <a href="#rid123">
          123
         </a>
         ]. Scopolamine patch is contraindicated in patients with angle closure glaucoma [
         <a href="#rid124">
          124
         </a>
         ].
        </p>
        <p>
         Outside the United States,
         <a class="drug drug_general" data-topicid="9915" href="/z/d/drug information/9915.html" rel="external">
          scopolamine
         </a>
         is available as an IV preparation as well.
        </p>
        <p class="headingAnchor" id="H2753307243">
         <span class="h4">
          Antidopaminergics
         </span>
         <span class="headingEndMark">
          —
         </span>
         The antidopaminergic class of antiemetics includes
         <a class="drug drug_general" data-topicid="9395" href="/z/d/drug information/9395.html" rel="external">
          droperidol
         </a>
         ,
         <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">
          haloperidol
         </a>
         , and
         <a class="drug drug_general" data-topicid="127253" href="/z/d/drug information/127253.html" rel="external">
          amisulpride
         </a>
         . Low doses of droperidol and haloperidol are as effective as
         <a class="drug drug_general" data-topicid="9719" href="/z/d/drug information/9719.html" rel="external">
          ondansetron
         </a>
         for PONV prophylaxis (droperidol 1.25 mg IV; RR 0.74 versus placebo) [
         <a href="#rid125">
          125,126
         </a>
         ], though they are associated with an increase in sedation [
         <a href="#rid127">
          127
         </a>
         ]. The US Food and Drug Administration (FDA) issued a "black box" warning regarding the potential for sudden cardiac death with droperidol in 2001. Since then, droperidol has rarely been used in the United States, though at the doses recommended for PONV prophylaxis, the risk of adverse cardiac events is extremely low. The butyrophenones are associated with an increase in the QT interval to a degree that is similar to ondansetron [
         <a href="#rid128">
          128
         </a>
         ]. Administration of ondansetron with droperidol or with haloperidol is more effective for PONV than either drug alone, without additional QT prolongation [
         <a href="#rid129">
          129-131
         </a>
         ]. Similar to ondansetron, butyrophenones should be avoided for patients at increased risk of QT prolongation  (
         <a class="graphic graphic_table graphicRef57431" href="/z/d/graphic/57431.html" rel="external">
          table 4
         </a>
         ).
        </p>
        <p>
         Both
         <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">
          haloperidol
         </a>
         and
         <a class="drug drug_general" data-topicid="9395" href="/z/d/drug information/9395.html" rel="external">
          droperidol
         </a>
         are typically administered as a single IV dose at the end of surgery. Haloperidol may also be administered orally or intramuscularly (IM). These drugs are not administered for POV prophylaxis for children.
        </p>
        <p>
         For patients who receive
         <a class="drug drug_general" data-topicid="9395" href="/z/d/drug information/9395.html" rel="external">
          droperidol
         </a>
         , we follow the FDA recommendation to monitor ECG for arrhythmias for two to three hours after administration [
         <a href="#rid128">
          128
         </a>
         ].
        </p>
        <p>
         <a class="drug drug_general" data-topicid="127253" href="/z/d/drug information/127253.html" rel="external">
          Amisulpride
         </a>
         is a dopamine receptor antagonist that was approved by the FDA in February 2020 for use in prevention and treatment of PONV [
         <a href="#rid132">
          132
         </a>
         ]. Amisulpride 5 mg is more efficacious than placebo in the prevention of PONV [
         <a href="#rid133">
          133,134
         </a>
         ]. Amisulpride 10 mg IV, not 5 mg, is more effective compared with placebo as rescue treatment of PONV in patients who have already received a PONV prophylaxis antiemetic that is not in the antidopaminergic class [
         <a href="#rid135">
          135
         </a>
         ]. Amisulpride can cause a mild elevation in serum prolactin, hypokalemia, chills, hypotension during injection, and pain at the injection site [
         <a href="#rid132">
          132
         </a>
         ]. Amisulpride should be avoided in patients who receive
         <a class="drug drug_general" data-topicid="9395" href="/z/d/drug information/9395.html" rel="external">
          droperidol
         </a>
         and in patients with congenital long QT syndrome. ECG monitoring should be performed in patients with cardiac conduction disorders and in patients on medications (ie,
         <a class="drug drug_general" data-topicid="9719" href="/z/d/drug information/9719.html" rel="external">
          ondansetron
         </a>
         ) which cause QT prolongation [
         <a href="#rid136">
          136
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Droperidol
         </strong>
         – 0.625 to 1.25 mg IV.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Haloperidol
         </strong>
         – 1 mg IV, or 1 mg oral, or 1 mg IM.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Amisulpride
         </strong>
         – 5 mg IV injected over one to two minutes at induction of anesthesia for prevention of PONV [
         <a href="#rid137">
          137
         </a>
         ]; 10 mg IV injected over one to two minutes as a rescue antiemetic after surgery if an antidopaminergic agent has not already been administered previously [
         <a href="#rid135">
          135
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H766421411">
         <span class="h4">
          Neurokinin 1 receptor antagonists
         </span>
         <span class="headingEndMark">
          —
         </span>
         The neurokinin 1 (NK1) receptor antagonists comprise a relatively new class of long-acting antiemetics that may be especially effective for prevention of POV and PDNV. In a network meta-analysis of 585 randomized trials (97,516 patients) involving 44 single drugs and 51 drug combinations, the NK1 receptor antagonists were the most effective class of antiemetics, and as effective when administered alone as other drug combinations [
         <a href="#rid67">
          67
         </a>
         ].
         <a class="drug drug_general" data-topicid="9032" href="/z/d/drug information/9032.html" rel="external">
          Fosaprepitant
         </a>
         was the single most effective antiemetic, though this conclusion was based on a very small number of studies that compared it with only placebo or
         <a class="drug drug_general" data-topicid="9719" href="/z/d/drug information/9719.html" rel="external">
          ondansetron
         </a>
         , and the evidence was of moderate quality. The only NK1 receptor antagonist that is FDA approved for PONV is oral
         <a class="drug drug_general" data-topicid="9305" href="/z/d/drug information/9305.html" rel="external">
          aprepitant
         </a>
         .
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9305" href="/z/d/drug information/9305.html" rel="external">
          Aprepitant
         </a>
         and
         <a class="drug drug_general" data-topicid="9032" href="/z/d/drug information/9032.html" rel="external">
          fosaprepitant
         </a>
         may reduce the efficacy of hormonal contraceptives [
         <a href="#rid138">
          138
         </a>
         ]. Patients should be instructed to use a non-hormonal method of contraception while using and following the last dose of these drugs [
         <a href="#rid139">
          139,140
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Aprepitant
         </strong>
         <strong>
         </strong>
         –
         <a class="drug drug_general" data-topicid="9305" href="/z/d/drug information/9305.html" rel="external">
          Aprepitant
         </a>
         is a neurokinin 1 (NK1) receptor antagonist available in oral and intravenous formulations. Aprepitant has a half-life of 40 hours [
         <a href="#rid58">
          58
         </a>
         ]. Compared with
         <a class="drug drug_general" data-topicid="9719" href="/z/d/drug information/9719.html" rel="external">
          ondansetron
         </a>
         alone [
         <a href="#rid141">
          141,142
         </a>
         ], and compared with ondansetron when both drugs have been administered with
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         [
         <a href="#rid143">
          143
         </a>
         ], aprepitant has been found to be equally effective for prevention of postoperative nausea and more effective for preventing vomiting at 24 and 48 hours.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Aprepitant
         </strong>
         <strong>
          dose
         </strong>
         – Adults, 40 mg orally preoperatively [
         <a href="#rid144">
          144-146
         </a>
         ]; or 32 mg IV over 30 seconds preoperatively
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Fosaprepitant
         </strong>
         <strong>
         </strong>
         –
         <strong>
         </strong>
         <a class="drug drug_general" data-topicid="9032" href="/z/d/drug information/9032.html" rel="external">
          Fosaprepitant
         </a>
         is a prodrug of
         <a class="drug drug_general" data-topicid="9305" href="/z/d/drug information/9305.html" rel="external">
          aprepitant
         </a>
         and is available only in IV form.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Fosaprepitant
         </strong>
         <strong>
          dose
         </strong>
         –
         <strong>
         </strong>
         150 mg IV preoperatively [
         <a href="#rid147">
          147
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Rolapitant
         </strong>
         <strong>
         </strong>
         –
         <strong>
         </strong>
         <a class="drug drug_general" data-topicid="103785" href="/z/d/drug information/103785.html" rel="external">
          Rolapitant
         </a>
         is a long-acting NK1 antagonist that is available in the United States in oral-form 90 mg tabs, and as an injectable emulsion for prevention of CINV (166.5 mg IV injected over 30 minutes). Rolapitant may be particularly effective for PDNV because of its very long half-life of 180 hours. A prospective dose ranging study of 600 high-risk patients reported that doses of ≥70 mg orally reduced emesis at 72 and 120 hours compared with placebo and with
         <a class="drug drug_general" data-topicid="9719" href="/z/d/drug information/9719.html" rel="external">
          ondansetron
         </a>
         [
         <a href="#rid148">
          148
         </a>
         ]. The intravenous preparation has not been studied for PONV prophylaxis.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Rolapitant
         </strong>
         <strong>
          dose
         </strong>
         – Adults, 90 mg oral, preoperatively [
         <a href="#rid148">
          148
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3187996832">
         <span class="h4">
          Antihistamines
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="8896" href="/z/d/drug information/8896.html" rel="external">
          Dimenhydrinate
         </a>
         and
         <a class="drug drug_general" data-topicid="9369" href="/z/d/drug information/9369.html" rel="external">
          diphenhydramine
         </a>
         are antihistamines with antiemetic efficacy similar to reported efficacy for
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         ,
         <a class="drug drug_general" data-topicid="9395" href="/z/d/drug information/9395.html" rel="external">
          droperidol
         </a>
         , and the 5-HT
         <sub>
          3
         </sub>
         antagonists at a dose of 1 mg/kg IV for adults, and 0.5 mg/kg, maximum 25 mg in children [
         <a href="#rid149">
          149
         </a>
         ], though direct comparisons have not been done. Dimenhydrinate can also be administered IM, orally, and rectally. Dose responses and optimal timing of administration have not been established.
        </p>
        <p>
         Common side effects of
         <a class="drug drug_general" data-topicid="8896" href="/z/d/drug information/8896.html" rel="external">
          dimenhydrinate
         </a>
         include sedation, dry mouth, dizziness, and urinary retention. In children, concerns for sedation and the possibility of emergence delirium related to urinary retention have limited the routine use of this drug.
        </p>
        <p class="headingAnchor" id="H978039586">
         <span class="h4">
          Phenothiazines
         </span>
         <span class="headingEndMark">
          —
         </span>
         The phenothiazines as a group are most effective at treating opioid-induced nausea and vomiting. Their use for PONV is limited by sedation at high doses and extrapyramidal effects. Data are limited regarding optimal doses and timing of administration. These drugs are not usually administered for children for POV prophylaxis.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9820" href="/z/d/drug information/9820.html" rel="external">
          Promethazine
         </a>
         <strong>
         </strong>
         –
         <strong>
         </strong>
         6.25 to 12.5 mg IV at induction of anesthesia [
         <a href="#rid150">
          150,151
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         Note: Extravasation of
         <a class="drug drug_general" data-topicid="9820" href="/z/d/drug information/9820.html" rel="external">
          promethazine
         </a>
         into subcutaneous tissues is likely to cause damage. The IV should be tested for patency and visible during administration of the drug. Promethazine should be diluted with
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         to a concentrations ≤1 mg/mL and infused over at least 20 minutes.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9816" href="/z/d/drug information/9816.html" rel="external">
          Prochlorperazine
         </a>
         <strong>
         </strong>
         –
         <strong>
         </strong>
         5 to 10 mg IV at the end of surgery [
         <a href="#rid152">
          152
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4207421783">
         <span class="h4">
          Propofol
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          Propofol
         </a>
         is a sedative hypnotic that is used for induction and maintenance of anesthesia and for sedation. Propofol is an antiemetic when administered at doses required for induction and maintenance for TIVA [
         <a href="#rid68">
          68,153-156
         </a>
         ] and when administered at subhypnotic doses in adults [
         <a href="#rid157">
          157
         </a>
         ] and children [
         <a href="#rid158">
          158
         </a>
         ]. In addition to a direct antiemetic effect, propofol may reduce PONV by reducing the required concentration of volatile anesthetic. (See
         <a class="local">
          'Anesthetic factors'
         </a>
         above.)
        </p>
        <p>
         In one study, 80 children who underwent tonsillectomy with
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         PONV prophylaxis were randomly assigned to receive a
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         bolus (1 mg/kg IV) followed by low-dose infusion (20 mcg/kg/minute IV) until the end of surgery, or no propofol [
         <a href="#rid158">
          158
         </a>
         ]. A higher percentage of those assigned to propofol were free of vomiting or retching for the initial 24 hours after surgery (75 versus 38 percent).
        </p>
        <p class="headingAnchor" id="H3571900129">
         <span class="h4">
          Metoclopramide
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9642" href="/z/d/drug information/9642.html" rel="external">
          Metoclopramide
         </a>
         is a relatively weak antiemetic that is rarely administered as PONV prophylaxis in adults or children.
        </p>
        <p>
         The literature on the efficacy of
         <a class="drug drug_general" data-topicid="9642" href="/z/d/drug information/9642.html" rel="external">
          metoclopramide
         </a>
         as an antiemetic for PONV is controversial. A number of published studies of antiemetics from a single author have been retracted from publication, including studies on metoclopramide [
         <a href="#rid159">
          159
         </a>
         ]. Meta-analyses including some of those studies had reported that metoclopramide was ineffective for prevention of PONV. However, a subsequent meta-analysis that excluded the retracted studies found that the usual adult dose of metoclopramide of 10 mg IV reduced the incidence of 24-hour PONV (odds ratio [OR] 0.58) [
         <a href="#rid160">
          160
         </a>
         ]. However, metoclopramide in usual doses is not as effective as other commonly used antiemetics. In a meta-analysis of trials (without the retracted studies) comparing antiemetics,
         <a class="drug drug_general" data-topicid="9719" href="/z/d/drug information/9719.html" rel="external">
          ondansetron
         </a>
         was found to be 57 percent more effective than metoclopramide 10 mg IV for PONV prevention [
         <a href="#rid125">
          125
         </a>
         ].
        </p>
        <p>
         In addition, studies in both adults [
         <a href="#rid41">
          41
         </a>
         ] and children [
         <a href="#rid52">
          52
         </a>
         ] report that
         <a class="drug drug_general" data-topicid="9642" href="/z/d/drug information/9642.html" rel="external">
          metoclopramide
         </a>
         is effective only at doses higher than usually used (25 to 50 mg IV in adults, 0.15 to 0.25 mg/kg in children). We typically do not administer these high doses because of increasing risk of adverse effects including hypotension, tachycardia, and rarely extrapyramidal symptoms.
        </p>
        <p>
         Extrapyramidal symptoms may be as much as 20-fold more common in children compared with adults [
         <a href="#rid161">
          161
         </a>
         ]. In infants, prolonged clearance may increase serum concentrations of
         <a class="drug drug_general" data-topicid="9642" href="/z/d/drug information/9642.html" rel="external">
          metoclopramide
         </a>
         ; administration should be avoided for children &lt;1 year of age. In older children, metoclopramide should only be administered when other antiemetics cannot be used, at a dose of 0.1 mg/kg IV, maximum 10 mg. (See
         <a class="drug drug_pediatric" href="/z/d/drug information/12602.html" rel="external">
          "Metoclopramide: Pediatric drug information"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4194392610">
         <span class="h4">
          Midazolam
         </span>
         <span class="headingEndMark">
          —
         </span>
         The literature on the efficacy of
         <a class="drug drug_general" data-topicid="9650" href="/z/d/drug information/9650.html" rel="external">
          midazolam
         </a>
         for PONV prophylaxis is inconclusive. Meta-analyses of trials of perioperative midazolam have reported 38 to 55 percent reduction in overall PONV [
         <a href="#rid162">
          162,163
         </a>
         ]. However, there was high risk of bias in the included studies, and a clinically relevant increase in postoperative sedation could not be ruled out.
        </p>
        <p>
         We do not administer
         <a class="drug drug_general" data-topicid="9650" href="/z/d/drug information/9650.html" rel="external">
          midazolam
         </a>
         solely for PONV prophylaxis because of the potential for postoperative sedation and delirium in some patient populations (eg, older adults, mentally ill).
        </p>
        <p class="headingAnchor" id="H757787398">
         <span class="h4">
          Cannabinoids
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cannabinoids may be effective for treatment of CINV. However, a randomized trial involving 340 patients with a high risk of PONV who underwent general anesthesia reported that a single preoperative dose of
         <a class="drug drug_general" data-topicid="9995" href="/z/d/drug information/9995.html" rel="external">
          nabilone
         </a>
         0.5 mg orally, in addition to routine PONV prophylaxis, had no effect on the incidence of PONV, pain scores, or opioid consumption [
         <a href="#rid164">
          164
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2934610509">
         <span class="h4">
          Olanzapine
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          Olanzapine
         </a>
         is a second-generation antipsychotic that blocks both serotonin type two 5-hydroxytryptamine (5-HT2) receptors and dopamine D2 receptors, and is used for antiemetic therapy for highly emetogenic chemotherapy regimens. (See
         <a class="medical medical_review" href="/z/d/html/1151.html" rel="external">
          "Prevention of chemotherapy-induced nausea and vomiting in adults", section on 'Olanzapine'
         </a>
         .)
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          Olanzapine
         </a>
         has a peak effect at six hours after oral administration and half-life of 30 hours, making it potentially useful for prevention of PDNV. In one single institution randomized trial, administration of olanzapine 10 mg orally preoperatively in addition to
         <a class="drug drug_general" data-topicid="9719" href="/z/d/drug information/9719.html" rel="external">
          ondansetron
         </a>
         and
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         reduced the incidence of nausea and vomiting in the first 24 postoperative hours by approximately 60 percent, compared with the other drugs alone [
         <a href="#rid165">
          165
         </a>
         ]. Similarly, in another single institution randomized trial including 100 patients with multiple risk factors for PONV plus a history of chemotherapy induced nausea and vomiting, addition of preoperative olanzapine to multidrug prophylaxis with dexamethasone, ondansetron, and the use of
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         anesthesia reduced the incidence of PONV in the first 24 hours by 60 percent (26 versus 63 percent) [
         <a href="#rid166">
          166
         </a>
         ].
        </p>
        <p>
         The role of
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          olanzapine
         </a>
         for PONV prophylaxis in adults and children, and optimal doses for this purpose have not been established. Olanzapine is associated with sedation, and doses should be reduced for older patients.
        </p>
        <p class="headingAnchor" id="H3680983641">
         <span class="h3">
          Combination therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         We agree with guidelines that recommend a combination of at least two antiemetics from different drug classes for PONV prophylaxis for any patient with risk factors for PONV [
         <a href="#rid56">
          56,57
         </a>
         ]. Combination therapy using different classes of drugs is usually more effective than single-drug therapy for PONV prophylaxis in both children and adults [
         <a href="#rid68">
          68,129,167-174
         </a>
         ]. This concept was demonstrated by a large randomized trial of six interventions for PONV prophylaxis, including three antiemetics (
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         ,
         <a class="drug drug_general" data-topicid="9395" href="/z/d/drug information/9395.html" rel="external">
          droperidol
         </a>
         , and
         <a class="drug drug_general" data-topicid="9719" href="/z/d/drug information/9719.html" rel="external">
          ondansetron
         </a>
         ) alone and in combination [
         <a href="#rid68">
          68
         </a>
         ]. Each antiemetic reduced PONV to a similar extent (RR 26 percent), and each drug acted independently, such that the risk reduction from combinations could be estimated by multiplying individual risk reductions.
        </p>
        <p>
         One single institution retrospective cohort study evaluated the effect of a combination of 5 prophylactic antiemetics on the incidence of PONV in 536 high risk surgical patients and case matched controls, all in a Veterans Administration hospital [
         <a href="#rid175">
          175
         </a>
         ]. Study patients were at high risk of PONV due to either receiving intrathecal
         <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">
          morphine
         </a>
         or having bariatric surgery, or both. The 5-drug regimen included preoperative
         <a class="drug drug_general" data-topicid="9760" href="/z/d/drug information/9760.html" rel="external">
          perphenazine
         </a>
         4 to 8 mg orally and
         <a class="drug drug_general" data-topicid="9305" href="/z/d/drug information/9305.html" rel="external">
          aprepitant
         </a>
         40 mg orally,
         <a class="drug drug_general" data-topicid="9369" href="/z/d/drug information/9369.html" rel="external">
          diphenhydramine
         </a>
         12.5mg IV.
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         4 mg IV, and either
         <a class="drug drug_general" data-topicid="9944" href="/z/d/drug information/9944.html" rel="external">
          Palonosetron
         </a>
         75 mcg IV or
         <a class="drug drug_general" data-topicid="9719" href="/z/d/drug information/9719.html" rel="external">
          ondansetron
         </a>
         8mg IV. The incidence of PONV requiring rescue on postoperative days 0 to 1 was 12 percent in patients who received the 5-drug regimen, compared with 22 percent in patients who received 1 to 4 drugs, and 56 percent for patients who received 0 to 1 drug. Further study is required before broadly advocating 5 drug PONV prophylaxis, even to patients who are at high risk for PONV.
        </p>
        <p>
         Existing data support the strategy to administer antiemetics from different drug classes [
         <a href="#rid176">
          176
         </a>
         ]. However, there is insufficient data to recommend one specific combination rather than others. The chosen combinations of prophylactic antiemetics must be individualized based on patient and surgical factors, and patients should be monitored for potential side effects when combining medications.
        </p>
        <p>
         Examples of studies of combinations of antiemetics include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          Dexamethasone
         </a>
         and
         <a class="drug drug_general" data-topicid="9719" href="/z/d/drug information/9719.html" rel="external">
          ondansetron
         </a>
         or
         <a class="drug drug_general" data-topicid="9944" href="/z/d/drug information/9944.html" rel="external">
          palonosetron
         </a>
         decreased the risk of PONV compared with only 5-HT3 receptor antagonist therapy [
         <a href="#rid174">
          174
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9305" href="/z/d/drug information/9305.html" rel="external">
          Aprepitant
         </a>
         with
         <a class="drug drug_general" data-topicid="9719" href="/z/d/drug information/9719.html" rel="external">
          ondansetron
         </a>
         is more effective than only monotherapy with ondansetron [
         <a href="#rid177">
          177,178
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9305" href="/z/d/drug information/9305.html" rel="external">
          Aprepitant
         </a>
         with
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         is more effective for preventing postoperative vomiting than
         <a class="drug drug_general" data-topicid="9719" href="/z/d/drug information/9719.html" rel="external">
          ondansetron
         </a>
         with dexamethasone [
         <a href="#rid143">
          143
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="127253" href="/z/d/drug information/127253.html" rel="external">
          Amisulpride
         </a>
         and
         <a class="drug drug_general" data-topicid="9719" href="/z/d/drug information/9719.html" rel="external">
          ondansetron
         </a>
         or
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         was more efficacious than lone therapy with ondansetron or dexamethasone in the reduction of PONV and in the necessity of a rescue antiemetic [
         <a href="#rid137">
          137
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Triple multimodal antiemetic prophylaxis with
         <a class="drug drug_general" data-topicid="9305" href="/z/d/drug information/9305.html" rel="external">
          aprepitant
         </a>
         80 mg,
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         4 to 8 mg, and
         <a class="drug drug_general" data-topicid="9719" href="/z/d/drug information/9719.html" rel="external">
          ondansetron
         </a>
         4 mg was more effective in the reduction of PONV compared with the combination of dexamethasone and ondansetron in patients having elective laparoscopic surgery under neuraxial blockade and TIVA [
         <a href="#rid179">
          179
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In children undergoing surgery for strabismus, the addition of
         <a class="drug drug_general" data-topicid="9719" href="/z/d/drug information/9719.html" rel="external">
          ondansetron
         </a>
         to
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         reduces POV from 23 to 5 percent [
         <a href="#rid180">
          180
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H959820222">
         <span class="h3">
          Nonpharmacologic techniques
         </span>
         <span class="headingEndMark">
          —
         </span>
         A number of nonpharmacologic methods have been suggested and studied for PONV prophylaxis. Of these, acupuncture seems to be the most promising.
        </p>
        <p class="headingAnchor" id="H695815149">
         <span class="h4">
          Acupuncture
         </span>
         <span class="headingEndMark">
          —
         </span>
         Stimulation of the pericardium-6 (P-6) acupuncture point may be effective for PONV prophylaxis for clinicians familiar with this technique  (
         <a class="graphic graphic_picture graphicRef107138" href="/z/d/graphic/107138.html" rel="external">
          picture 1
         </a>
         ). A meta-analysis of 59 studies including 7700 adults and children reported that acupoint stimulation with a variety of techniques (eg, acupuncture needles, acupressure wristbands) was as effective as the commonly used antiemetics for prevention of PONV [
         <a href="#rid181">
          181
         </a>
         ]. A 2020 meta-anaylsis of 16 randomized trials in children found that acupuncture reduced the risk of PONV and antiemetic use, particularly during the first four hours after the procedure [
         <a href="#rid182">
          182
         </a>
         ]. The quality of the evidence was rated as low.
        </p>
        <p>
         The side effects of acupuncture and acupressure are low, including skin redness or irritation and, very rarely, nerve damage, bleeding, or skin infection [
         <a href="#rid183">
          183
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H959820240">
         <span class="h4">
          Isopropyl alcohol
         </span>
         <span class="headingEndMark">
          —
         </span>
         Inhalation of isopropyl alcohol (eg, having the patient inhale alcohol from a skin prep pack or alcohol-soaked sponge) may be a modestly effective short-term treatment for PONV. A meta-analysis including six small studies found that alcohol inhalation reduced the need for rescue antiemetics compared with placebo, but that it was less effective than standard antiemetics [
         <a href="#rid184">
          184
         </a>
         ].
        </p>
        <p>
         Isopropyl alcohol is a readily available, low-risk treatment that may be most useful for immediate administration while other antiemetics are prepared for administration.
        </p>
        <p class="headingAnchor" id="H2230341374">
         <span class="h1">
          RESCUE THERAPY
         </span>
         <span class="headingEndMark">
          —
         </span>
         When postoperative nausea and vomiting (PONV) occurs in the post-anesthesia care unit (PACU) or operating room, rescue treatment should include a drug from a different class than those that have already been administered unless the effect of the first drug has worn off or a potentially inadequate dose has been administered [
         <a href="#rid185">
          185
         </a>
         ].
        </p>
        <p>
         The serotonin receptor antagonists are particularly beneficial as rescue drugs in the PACU, especially for same-day surgery patients, because they are nonsedating. (See
         <a class="local">
          'Serotonin (5-hydroxytryptamine) receptor antagonists'
         </a>
         above.)
        </p>
        <p>
         Whereas
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         is an effective prophylactic antiemetic, it may be less effective as a rescue medication. In a multicenter trial of 280 patients who had PONV after general anesthesia without PONV prophylaxis, dexamethasone (at doses of 3, 6, or 12 mg IV) was ineffective for treatment of PONV within the first 24 hours after surgery, compared with placebo [
         <a href="#rid186">
          186
         </a>
         ]. Conclusions are limited by the small study size, and the fact that the study was stopped early for futility.
        </p>
        <p>
         For opioid-induced PONV or postoperative vomiting (POV), low-dose
         <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">
          naloxone
         </a>
         infusion (0.25 mcg/kg/hour IV) can reduce opioid-induced side effects including nausea and vomiting, without affecting analgesia [
         <a href="#rid187">
          187,188
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H959820332">
         <span class="h1">
          POSTDISCHARGE NAUSEA AND VOMITING
         </span>
         <span class="headingEndMark">
          —
         </span>
         Postdischarge nausea and vomiting (PDNV) (ie, nausea and vomiting within 48 hours of discharge) occurs in 37 percent of adult patients who undergo general anesthesia for same-day surgery [
         <a href="#rid21">
          21
         </a>
         ]. Risk factors for PDNV include those that predict PONV [
         <a href="#rid189">
          189
         </a>
         ] and, in addition, administration of opioids in the PACU and nausea in the PACU. A simplified risk scoring system has been developed for PDNV, including the following risk factors  (
         <a class="graphic graphic_figure graphicRef107494" href="/z/d/graphic/107494.html" rel="external">
          figure 3
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Female sex
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Age &lt;50
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         History of PONV
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Opioids administered in the PACU
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Nausea in the PACU
        </p>
        <p>
        </p>
        <p>
         Zero, one, two, three, four, and five risk factors are associated with a 7, 20, 28, 53, 60, and 90 percent incidence of PDNV, respectively [
         <a href="#rid21">
          21
         </a>
         ].
        </p>
        <p>
         Preventive strategies for PDNV include risk stratification followed by a multimodal prophylactic approach, similar to prophylaxis for PONV. Some options may be limited by availability of the newer antiemetics and formulary issues. The addition of either long-acting antiemetics (eg,
         <a class="drug drug_general" data-topicid="9305" href="/z/d/drug information/9305.html" rel="external">
          aprepitant
         </a>
         ,
         <a class="drug drug_general" data-topicid="9944" href="/z/d/drug information/9944.html" rel="external">
          palonosetron
         </a>
         , transdermal
         <a class="drug drug_general" data-topicid="9915" href="/z/d/drug information/9915.html" rel="external">
          scopolamine
         </a>
         ) or repeat, scheduled dosing of shorter-acting medications in the postoperative period (eg,
         <a class="drug drug_general" data-topicid="9719" href="/z/d/drug information/9719.html" rel="external">
          ondansetron
         </a>
         oral disintegrating tablet [ODT]) may reduce PDNV.
        </p>
        <p>
         In one study, high-risk patients were randomly assigned to standard prophylaxis with
         <a class="drug drug_general" data-topicid="9719" href="/z/d/drug information/9719.html" rel="external">
          ondansetron
         </a>
         4 mg intravenously (IV), or a study regimen including
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         8 mg IV and ondansetron 4 mg IV intraoperatively, and ODT 8 mg to be taken on discharge and in the morning of postoperative days 1 and 2 [
         <a href="#rid190">
          190
         </a>
         ]. The study regimen reduced the incidence of postdischarge nausea (20 percent versus 57 percent) and vomiting (3 percent versus 20 percent) compared with standard prophylaxis.
        </p>
        <p>
         The incidence of PDNV in children may be lower than in adults. In a prospective observational study of 1041 children who underwent ambulatory surgery, the incidence of PDNV was 14 percent [
         <a href="#rid191">
          191
         </a>
         ]. Risk factors for PDNV included perioperative opioid administration, inhalation anesthetics, and the use of opioid medications at home; no patient who received total intravenous anesthesia (TIVA) had PDNV. There was no association between PDNV and age, gender, duration of anesthesia, use of
         <a class="drug drug_general" data-topicid="10086" href="/z/d/drug information/10086.html" rel="external">
          nitrous oxide
         </a>
         (N
         <sub>
          2
         </sub>
         O) for maintenance of anesthetic, intraoperative antiemetic administration, airway management strategy, or the length of time from recovery room discharge to first oral intake.
        </p>
        <p class="headingAnchor" id="H2737199774">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/116124.html" rel="external">
          "Society guideline links: Postoperative nausea and vomiting"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H554591314">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/114152.html" rel="external">
          "Patient education: Nausea and vomiting after surgery (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H959820338">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Incidence
         </strong>
         –
         <strong>
         </strong>
         Postoperative nausea and vomiting (PONV) occurs in approximately 30 percent of adults and children after general anesthesia, and in up to 80 percent of high-risk patients. (See
         <a class="local">
          'Risk factors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Risk stratification
         </strong>
         –
         <strong>
         </strong>
         The preventive strategy is based on risk stratification that takes into account patient, anesthesia, and procedure specific factors. (See
         <a class="local">
          'Risk factors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Adults
         </strong>
         – We use Apfel's simplified risk score to evaluate adults. This risk score includes four factors: female gender, nonsmoking, history of motion sickness or PONV, and expected administration of postoperative opioids  (
         <a class="graphic graphic_figure graphicRef107494" href="/z/d/graphic/107494.html" rel="external">
          figure 3
         </a>
         ). (See
         <a class="local">
          'Risk score for postoperative nausea and vomiting for adults'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Children
         </strong>
         – We use an alternative risk scoring system for children, which includes preoperative, intraoperative, and postoperative risk factors  (
         <a class="graphic graphic_table graphicRef130337" href="/z/d/graphic/130337.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Risk score for postoperative vomiting for children'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prophylaxis for all patients
         </strong>
         –
         <strong>
         </strong>
         Prophylaxis for all patients should include multimodal opioid-sparing postoperative pain control. Additional prophylactic interventions may include the following:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Modification of the anesthetic (eg, avoiding general anesthesia, use of total intravenous anesthesia with
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         ) (see
         <a class="local">
          'Reduction of baseline risk'
         </a>
         above)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Antiemetics (see
         <a class="local">
          'Antiemetics'
         </a>
         above)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Acupuncture (see
         <a class="local">
          'Acupuncture'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prophylaxis for adults
         </strong>
         –
         <strong>
         </strong>
         For all patients with one or more risk factors for PONV, we recommend prophylaxis. (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ). We suggest multimodal prophylaxis, with antiemetics from different drug classes, and possibly modification of the anesthetic  (
         <a class="graphic graphic_algorithm graphicRef111057" href="/z/d/graphic/111057.html" rel="external">
          algorithm 1
         </a>
         and
         <a class="graphic graphic_table graphicRef130338" href="/z/d/graphic/130338.html" rel="external">
          table 3
         </a>
         ) (
         <a class="grade" href="https:///uptodate/show/grade_4" rel="external">
          Grade 2A
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Adults with ≥3 risk factors
         </strong>
         – For these patients
         <strong>
         </strong>
         we use three or more interventions, including at least three antiemetics from different drug classes.
         <strong>
         </strong>
         We use regional anesthesia if possible or TIVA with
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         if general anesthesia is required, opioid-sparing anesthesia techniques, and we administer transdermal
         <a class="drug drug_general" data-topicid="9915" href="/z/d/drug information/9915.html" rel="external">
          scopolamine
         </a>
         1.5 mg,
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         4 to 8 mg intravenous (IV), and
         <a class="drug drug_general" data-topicid="9719" href="/z/d/drug information/9719.html" rel="external">
          ondansetron
         </a>
         4 mg IV for prophylaxis. (See
         <a class="local">
          'Adults with ≥3 risk factors'
         </a>
         above and
         <a class="local">
          'Options for prophylaxis in adults and children'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Adults with one or two risk factors
         </strong>
         – For these patients we use ≥2 interventions, including at least two antiemetics from different drug classes. We usually administer
         <a class="drug drug_general" data-topicid="9719" href="/z/d/drug information/9719.html" rel="external">
          ondansetron
         </a>
         4 mg IV and
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         4 to 8 mg IV and may also choose to modify the anesthetic technique (ie, regional anesthesia or TIVA with
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         ) or perform acupuncture.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Adults without risk factors
         </strong>
         –
         <strong>
         </strong>
         For adults without risk factors who receive inhalation anesthesia or TIVA with opioids, we administer two antiemetics. We usually administer
         <a class="drug drug_general" data-topicid="9719" href="/z/d/drug information/9719.html" rel="external">
          ondansetron
         </a>
         4 mg IV and
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         4 to 8 mg IV in this setting.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         For adults without risk factors who receive regional anesthesia or TIVA with
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         without perioperative opioids, we do not administer PONV prophylaxis, though others do.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prophylaxis for children
         </strong>
         (
         <a class="graphic graphic_algorithm graphicRef130341" href="/z/d/graphic/130341.html" rel="external">
          algorithm 2
         </a>
         and
         <a class="graphic graphic_table graphicRef130338" href="/z/d/graphic/130338.html" rel="external">
          table 3
         </a>
         ) (see
         <a class="local">
          'Children'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Children with ≥3 risk factors
         </strong>
         – We offer regional anesthesia with sedation to older high risk children if possible. If general anesthesia is required, we use TIVA with
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         . We administer
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         0.25 mg/kg IV, maximum 4 mg, and
         <a class="drug drug_general" data-topicid="9719" href="/z/d/drug information/9719.html" rel="external">
          ondansetron
         </a>
         0.1 mg IV, maximum 4 mg for prophylaxis.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Children with one or two risk factors
         </strong>
         –
         <strong>
         </strong>
         We use the same approach as for high risk children, without using TIVA rather than inhalation agents for general anesthesia.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Children without risk factors
         </strong>
         – We administer
         <a class="drug drug_general" data-topicid="9719" href="/z/d/drug information/9719.html" rel="external">
          ondansetron
         </a>
         0.1 mg/kg IV, maximum 4 mg, for prophylaxis, though it is reasonable to administer no prophylaxis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Antiemetics
         </strong>
         –
         <strong>
         </strong>
         Antiemetics commonly used for prophylaxis and treatment of PONV are shown in a table  (
         <a class="graphic graphic_table graphicRef130338" href="/z/d/graphic/130338.html" rel="external">
          table 3
         </a>
         ). (See
         <a class="local">
          'Antiemetics'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         General principles for their use include the following (see
         <a class="local">
          'General principles'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The most commonly used antiemetics reduce the risk of PONV by approximately 25 percent  (
         <a class="graphic graphic_table graphicRef65891" href="/z/d/graphic/65891.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The absolute benefit of an antiemetic depends on the degree of baseline risk; higher-risk patients benefit more than low-risk patients.
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The effects of drugs that act on different receptors are additive.
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         All antiemetics have side effects, some more serious than others.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Rescue therapy
         </strong>
         –
         <strong>
         </strong>
         Rescue therapy for PONV in the post-anesthesia care unit (PACU) or operating room should include a drug from a different class than those that have already been administered, unless the effect of the first drug has worn off or a potentially inadequate dose has been administered. (See
         <a class="local">
          'Rescue therapy'
         </a>
         above and
         <a class="local">
          'Our strategy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Postdischarge nausea and vomiting
         </strong>
         – Postdischarge nausea and vomiting (PDNV) may occur in as many as 37 percent of adults who undergo same-day surgery. Risk factors for PDNV include nausea in the PACU and opioids administered in the PACU, in addition to the risk factors for PONV  (
         <a class="graphic graphic_figure graphicRef107494" href="/z/d/graphic/107494.html" rel="external">
          figure 3
         </a>
         ). Prophylaxis may include administration of longer-acting antiemetics (eg,
         <a class="drug drug_general" data-topicid="9305" href="/z/d/drug information/9305.html" rel="external">
          aprepitant
         </a>
         ,
         <a class="drug drug_general" data-topicid="9944" href="/z/d/drug information/9944.html" rel="external">
          palonosetron
         </a>
         , transdermal
         <a class="drug drug_general" data-topicid="9915" href="/z/d/drug information/9915.html" rel="external">
          scopolamine
         </a>
         ) or repeat, scheduled doses of the shorter-acting antiemetics. (See
         <a class="local">
          'Postdischarge nausea and vomiting'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Macario A, Weinger M, Carney S, Kim A. Which clinical anesthesia outcomes are important to avoid? The perspective of patients. Anesth Analg 1999; 89:652.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fortier J, Chung F, Su J. Unanticipated admission after ambulatory surgery--a prospective study. Can J Anaesth 1998; 45:612.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hill RP, Lubarsky DA, Phillips-Bute B, et al. Cost-effectiveness of prophylactic antiemetic therapy with ondansetron, droperidol, or placebo. Anesthesiology 2000; 92:958.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bashashati M, McCallum RW. Neurochemical mechanisms and pharmacologic strategies in managing nausea and vomiting related to cyclic vomiting syndrome and other gastrointestinal disorders. Eur J Pharmacol 2014; 722:79.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Becker DE. Nausea, vomiting, and hiccups: a review of mechanisms and treatment. Anesth Prog 2010; 57:150.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spiller R. Recent advances in understanding the role of serotonin in gastrointestinal motility in functional bowel disorders: alterations in 5-HT signalling and metabolism in human disease. Neurogastroenterol Motil 2007; 19 Suppl 2:25.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Horn CC, Wallisch WJ, Homanics GE, Williams JP. Pathophysiological and neurochemical mechanisms of postoperative nausea and vomiting. Eur J Pharmacol 2014; 722:55.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bountra C, Gale JD, Gardner CJ, et al. Towards understanding the aetiology and pathophysiology of the emetic reflex: novel approaches to antiemetic drugs. Oncology 1996; 53 Suppl 1:102.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mitchelson F. Pharmacological agents affecting emesis. A review (Part I). Drugs 1992; 43:295.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cohen MM, Duncan PG, DeBoer DP, Tweed WA. The postoperative interview: assessing risk factors for nausea and vomiting. Anesth Analg 1994; 78:7.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Apfel CC, Läärä E, Koivuranta M, et al. A simplified risk score for predicting postoperative nausea and vomiting: conclusions from cross-validations between two centers. Anesthesiology 1999; 91:693.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koivuranta M, Läärä E, Snåre L, Alahuhta S. A survey of postoperative nausea and vomiting. Anaesthesia 1997; 52:443.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kranke P, Eberhart LH, Toker H, et al. A prospective evaluation of the POVOC score for the prediction of postoperative vomiting in children. Anesth Analg 2007; 105:1592.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Apfel CC, Heidrich FM, Jukar-Rao S, et al. Evidence-based analysis of risk factors for postoperative nausea and vomiting. Br J Anaesth 2012; 109:742.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sinclair DR, Chung F, Mezei G. Can postoperative nausea and vomiting be predicted? Anesthesiology 1999; 91:109.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eberhart LH, Geldner G, Kranke P, et al. The development and validation of a risk score to predict the probability of postoperative vomiting in pediatric patients. Anesth Analg 2004; 99:1630.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eberhart LH, Morin AM, Guber D, et al. Applicability of risk scores for postoperative nausea and vomiting in adults to paediatric patients. Br J Anaesth 2004; 93:386.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rowley MP, Brown TC. Postoperative vomiting in children. Anaesth Intensive Care 1982; 10:309.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Palazzo M, Evans R. Logistic regression analysis of fixed patient factors for postoperative sickness: a model for risk assessment. Br J Anaesth 1993; 70:135.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stadler M, Bardiau F, Seidel L, et al. Difference in risk factors for postoperative nausea and vomiting. Anesthesiology 2003; 98:46.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Apfel CC, Philip BK, Cakmakkaya OS, et al. Who is at risk for postdischarge nausea and vomiting after ambulatory surgery? Anesthesiology 2012; 117:475.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           da Silva HB, Sousa AM, Guimarães GM, et al. Does previous chemotherapy-induced nausea and vomiting predict postoperative nausea and vomiting? Acta Anaesthesiol Scand 2015; 59:1145.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Apfel CC, Kranke P, Katz MH, et al. Volatile anaesthetics may be the main cause of early but not delayed postoperative vomiting: a randomized controlled trial of factorial design. Br J Anaesth 2002; 88:659.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fernández-Guisasola J, Gómez-Arnau JI, Cabrera Y, del Valle SG. Association between nitrous oxide and the incidence of postoperative nausea and vomiting in adults: a systematic review and meta-analysis. Anaesthesia 2010; 65:379.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tramèr M, Moore A, McQuay H. Omitting nitrous oxide in general anaesthesia: meta-analysis of intraoperative awareness and postoperative emesis in randomized controlled trials. Br J Anaesth 1996; 76:186.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hannon JD, Warner LL, Stewart TM, et al. Antinausea Protocol Reduces Hospital Length of Stay for Laparoscopic Nissen Fundoplication. J Cardiothorac Vasc Anesth 2020; 34:1853.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sneyd JR, Carr A, Byrom WD, Bilski AJ. A meta-analysis of nausea and vomiting following maintenance of anaesthesia with propofol or inhalational agents. Eur J Anaesthesiol 1998; 15:433.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           St Pierre M, Dunkel M, Rutherford A, Hering W. Does etomidate increase postoperative nausea? A double-blind controlled comparison of etomidate in lipid emulsion with propofol for balanced anaesthesia. Eur J Anaesthesiol 2000; 17:634.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Laskowski K, Stirling A, McKay WP, Lim HJ. A systematic review of intravenous ketamine for postoperative analgesia. Can J Anaesth 2011; 58:911.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Subramaniam K, Subramaniam B, Steinbrook RA. Ketamine as adjuvant analgesic to opioids: a quantitative and qualitative systematic review. Anesth Analg 2004; 99:482.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gorlin AW, Rosenfeld DM, Ramakrishna H. Intravenous sub-anesthetic ketamine for perioperative analgesia. J Anaesthesiol Clin Pharmacol 2016; 32:160.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vallejo MC, Romeo RC, Davis DJ, Ramanathan S. Propofol-ketamine versus propofol-fentanyl for outpatient laparoscopy: comparison of postoperative nausea, emesis, analgesia, and recovery. J Clin Anesth 2002; 14:426.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Felts JA, Poler SM, Spitznagel EL. Nitrous oxide, nausea, and vomiting after outpatient gynecologic surgery. J Clin Anesth 1990; 2:168.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bloomfield E, Porembka D, Grimes-Rice M. Avoidance of nitrous oxide and increased isoflurane during alfentanil based anesthesia decreases the incidence of postoperative nausea. Anesth Prog 1997; 44:27.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vanacker BF. The impact of nitrous oxide on postoperative nausea and vomiting after desflurane anesthesia for breast surgery. Acta Anaesthesiol Belg 1999; 50:77.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hovorka J, Korttila K, Erkola O. Nitrous oxide does not increase nausea and vomiting following gynaecological laparoscopy. Can J Anaesth 1989; 36:145.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taylor E, Feinstein R, White PF, Soper N. Anesthesia for laparoscopic cholecystectomy. Is nitrous oxide contraindicated? Anesthesiology 1992; 76:541.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ichinohe T, Kaneko Y. Nitrous oxide does not aggravate postoperative emesis after orthognathic surgery in female and nonsmoking patients. J Oral Maxillofac Surg 2007; 65:936.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mraovic B, Simurina T, Gan TJ. Nitrous oxide added at the end of isoflurane anesthesia hastens early recovery without increasing the risk for postoperative nausea and vomiting: a randomized clinical trial. Can J Anaesth 2018; 65:162.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Apfel CC, Kranke P, Eberhart LH, et al. Comparison of predictive models for postoperative nausea and vomiting. Br J Anaesth 2002; 88:234.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wallenborn J, Gelbrich G, Bulst D, et al. Prevention of postoperative nausea and vomiting by metoclopramide combined with dexamethasone: randomised double blind multicentre trial. BMJ 2006; 333:324.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peyton PJ, Wu CY. Nitrous oxide-related postoperative nausea and vomiting depends on duration of exposure. Anesthesiology 2014; 120:1137.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roberts GW, Bekker TB, Carlsen HH, et al. Postoperative nausea and vomiting are strongly influenced by postoperative opioid use in a dose-related manner. Anesth Analg 2005; 101:1343.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marret E, Kurdi O, Zufferey P, Bonnet F. Effects of nonsteroidal antiinflammatory drugs on patient-controlled analgesia morphine side effects: meta-analysis of randomized controlled trials. Anesthesiology 2005; 102:1249.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maund E, McDaid C, Rice S, et al. Paracetamol and selective and non-selective non-steroidal anti-inflammatory drugs for the reduction in morphine-related side-effects after major surgery: a systematic review. Br J Anaesth 2011; 106:292.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Remy C, Marret E, Bonnet F. Effects of acetaminophen on morphine side-effects and consumption after major surgery: meta-analysis of randomized controlled trials. Br J Anaesth 2005; 94:505.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martinez V, Guichard L, Fletcher D. Effect of combining tramadol and morphine in adult surgical patients: a systematic review and meta-analysis of randomized trials. Br J Anaesth 2015; 114:384.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martinez V, Beloeil H, Marret E, et al. Non-opioid analgesics in adults after major surgery: systematic review with network meta-analysis of randomized trials. Br J Anaesth 2017; 118:22.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cheng CR, Sessler DI, Apfel CC. Does neostigmine administration produce a clinically important increase in postoperative nausea and vomiting? Anesth Analg 2005; 101:1349.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yağan Ö, Taş N, Mutlu T, Hancı V. Comparison of the effects of sugammadex and neostigmine on postoperative nausea and vomiting. Braz J Anesthesiol 2017; 67:147.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hristovska AM, Duch P, Allingstrup M, Afshari A. Efficacy and safety of sugammadex versus neostigmine in reversing neuromuscular blockade in adults. Cochrane Database Syst Rev 2017; 8:CD012763.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tramèr M, Moore A, McQuay H. Prevention of vomiting after paediatric strabismus surgery: a systematic review using the numbers-needed-to-treat method. Br J Anaesth 1995; 75:556.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ferrari LR, Donlon JV. Metoclopramide reduces the incidence of vomiting after tonsillectomy in children. Anesth Analg 1992; 75:351.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Paxton D, Taylor RH, Gallagher TM, Crean PM. Postoperative emesis following otoplasty in children. Anaesthesia 1995; 50:1083.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Villeret I, Laffon M, Duchalais A, et al. Incidence of postoperative nausea and vomiting in paediatric ambulatory surgery. Paediatr Anaesth 2002; 12:712.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gan TJ, Belani KG, Bergese S, et al. Fourth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting. Anesth Analg 2020; 131:411.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Apfel CC, Turan A, Souza K, et al. Intravenous acetaminophen reduces postoperative nausea and vomiting: a systematic review and meta-analysis. Pain 2013; 154:677.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gan TJ, Diemunsch P, Habib AS, et al. Consensus guidelines for the management of postoperative nausea and vomiting. Anesth Analg 2014; 118:85.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Apfel CC, Meyer A, Orhan-Sungur M, et al. Supplemental intravenous crystalloids for the prevention of postoperative nausea and vomiting: quantitative review. Br J Anaesth 2012; 108:893.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jewer JK, Wong MJ, Bird SJ, et al. Supplemental perioperative intravenous crystalloids for postoperative nausea and vomiting. Cochrane Database Syst Rev 2019; 3:CD012212.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Puri S, Bandyopadhyay A, Ashok V. Supplemental intraoperative crystalloids for pediatric postoperative nausea and vomiting-A systematic review and meta-analysis. Paediatr Anaesth 2023; 33:38.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sanford EL, Zurakowski D, Litvinova A, et al. The association between high-volume intraoperative fluid administration and outcomes among pediatric patients undergoing large bowel resection. Paediatr Anaesth 2019; 29:315.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zorrilla-Vaca A, Marmolejo-Posso D, Stone A, et al. Perioperative Dextrose Infusion and Postoperative Nausea and Vomiting: A Meta-analysis of Randomized Trials. Anesth Analg 2019; 129:943.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yokoyama C, Mihara T, Kashiwagi S, et al. Effects of intravenous dextrose on preventing postoperative nausea and vomiting: A systematic review and meta-analysis with trial sequential analysis. PLoS One 2020; 15:e0231958.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khetarpal R, Chatrath V, Kaur J, et al. Impact of different intravenous fluids on blood glucose levels in nondiabetic patients undergoing elective major noncardiac surgeries. Anesth Essays Res 2016; 10:425.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rao V, Bala I, Jain D, Bharti N. Effect of intravenous dextrose administration on postoperative nausea and vomiting in patients undergoing laparoscopic cholecystectomy: A randomised controlled trial. Eur J Anaesthesiol 2017; 34:705.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weibel S, Rücker G, Eberhart LH, et al. Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis. Cochrane Database Syst Rev 2020; 10:CD012859.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Apfel CC, Korttila K, Abdalla M, et al. A factorial trial of six interventions for the prevention of postoperative nausea and vomiting. N Engl J Med 2004; 350:2441.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Elbakry AE, Sultan WE, Ibrahim E. A comparison between inhalational (Desflurane) and total intravenous anaesthesia (Propofol and dexmedetomidine) in improving postoperative recovery for morbidly obese patients undergoing laparoscopic sleeve gastrectomy: A double-blinded randomised controlled trial. J Clin Anesth 2018; 45:6.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tramèr MR, Reynolds DJ, Moore RA, McQuay HJ. Efficacy, dose-response, and safety of ondansetron in prevention of postoperative nausea and vomiting: a quantitative systematic review of randomized placebo-controlled trials. Anesthesiology 1997; 87:1277.
          </a>
         </li>
         <li class="breakAll">
          FDA Drug Safety Communication: New information regarding QT prolongation with ondansetron (Zofran). www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-new-information-regarding-qt-prolongation-ondansetron-zofran (Accessed on August 26, 2020).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cohen IT, Joffe D, Hummer K, Soluri A. Ondansetron oral disintegrating tablets: acceptability and efficacy in children undergoing adenotonsillectomy. Anesth Analg 2005; 101:59.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grover VK, Mathew PJ, Hegde H. Efficacy of orally disintegrating ondansetron in preventing postoperative nausea and vomiting after laparoscopic cholecystectomy: a randomised, double-blind placebo controlled study. Anaesthesia 2009; 64:595.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Davis PJ, Fertal KM, Boretsky KR, et al. The effects of oral ondansetron disintegrating tablets for prevention of at-home emesis in pediatric patients after ear-nose-throat surgery. Anesth Analg 2008; 106:1117.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zarate E, Watcha MF, White PF, et al. A comparison of the costs and efficacy of ondansetron versus dolasetron for antiemetic prophylaxis. Anesth Analg 2000; 90:1352.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Honkavaara P. Effect of ondansetron on nausea and vomiting after middle ear surgery during general anaesthesia. Br J Anaesth 1996; 76:316.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dershwitz M, Conant JA, Chang Y, et al. A randomized, double-blind, dose-response study of ondansetron in the prevention of postoperative nausea and vomiting. J Clin Anesth 1998; 10:314.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khalil SN, Roth AG, Cohen IT, et al. A double-blind comparison of intravenous ondansetron and placebo for preventing postoperative emesis in 1- to 24-month-old pediatric patients after surgery under general anesthesia. Anesth Analg 2005; 101:356.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dua N, Sethi N, Sood J, Jain P. Randomized double blind comparative study comparing efficacy of granisetron and ondansetron for the prophylactic control of postoperative nausea and vomiting in patients undergoing middle ear surgery. Indian J Otolaryngol Head Neck Surg 2014; 66:252.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sodhi K MB, Sodhi GS, Kumar M. A comparative study of granisetron, dexamethasone, and granisetron plus dexamethasone as prophylactic antiemetic therapy in female patients undergoing breast surgery. J Anaesthesiol Clin Pharmacol 2007; 23:373.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cieslak GD, Watcha MF, Phillips MB, Pennant JH. The dose-response relation and cost-effectiveness of granisetron for the prophylaxis of pediatric postoperative emesis. Anesthesiology 1996; 85:1076.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Philip BK, McLeskey CH, Chelly JE, et al. Pooled analysis of three large clinical trials to determine the optimal dose of dolasetron mesylate needed to prevent postoperative nausea and vomiting. The Dolasetron Prophylaxis Study Group. J Clin Anesth 2000; 12:1.
          </a>
         </li>
         <li class="breakAll">
          FDA Drug Safety Communication: Abnormal heart rhythms associated with use of Anzemet (dolasetron mesylate). Available at: https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-abnormal-heart-rhythms-associated-use-anzemet-dolasetron-mesylate (Accessed on June 28, 2020).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kranke P, Eberhart LH, Apfel CC, et al. [Tropisetron for prevention of postoperative nausea and vomiting: a quantitative systematic review]. Anaesthesist 2002; 51:805.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rojas C, Stathis M, Thomas AG, et al. Palonosetron exhibits unique molecular interactions with the 5-HT3 receptor. Anesth Analg 2008; 107:469.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rojas C, Thomas AG, Alt J, et al. Palonosetron triggers 5-HT(3) receptor internalization and causes prolonged inhibition of receptor function. Eur J Pharmacol 2010; 626:193.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kovac AL, Eberhart L, Kotarski J, et al. A randomized, double-blind study to evaluate the efficacy and safety of three different doses of palonosetron versus placebo in preventing postoperative nausea and vomiting over a 72-hour period. Anesth Analg 2008; 107:439.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Candiotti KA, Kovac AL, Melson TI, et al. A randomized, double-blind study to evaluate the efficacy and safety of three different doses of palonosetron versus placebo for preventing postoperative nausea and vomiting. Anesth Analg 2008; 107:445.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singh PM, Borle A, Gouda D, et al. Efficacy of palonosetron in postoperative nausea and vomiting (PONV)-a meta-analysis. J Clin Anesth 2016; 34:459.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Xiong C, Liu G, Ma R, et al. Efficacy of palonosetron for preventing postoperative nausea and vomiting: a systematic review and meta-analysis. Can J Anaesth 2015; 62:1268.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li Y, Wei X, Zhang S, et al. A Meta-Analysis of Palonosetron for the Prevention of Postoperative Nausea and Vomiting in Adults. J Perianesth Nurs 2015; 30:398.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yildirim MD, Cantekin K. Effect of palonosetron on postoperative nausea and vomiting in children following dental rehabilitation under general anesthesia. Pediatr Dent 2014; 36:7E.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bicer C, Aksu R, Ulgey A, et al. Different doses of palonosetron for the prevention of postoperative nausea and vomiting in children undergoing strabismus surgery. Drugs R D 2011; 11:29.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Choi YS, Shim JK, Yoon DH, et al. Effect of ramosetron on patient-controlled analgesia related nausea and vomiting after spine surgery in highly susceptible patients: comparison with ondansetron. Spine (Phila Pa 1976) 2008; 33:E602.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee S, Jeong S, Kim J, Jeong S. Effective Dose of Ramosetron for Prophylaxis of Postoperative Nausea and Vomiting in High-Risk Patients. Biomed Res Int 2015; 2015:951474.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang JJ, Ho ST, Lee SC, et al. The use of dexamethasone for preventing postoperative nausea and vomiting in females undergoing thyroidectomy: a dose-ranging study. Anesth Analg 2000; 91:1404.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Henzi I, Walder B, Tramèr MR. Dexamethasone for the prevention of postoperative nausea and vomiting: a quantitative systematic review. Anesth Analg 2000; 90:186.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weren M, Demeere JL. Methylprednisolone vs. dexamethasone in the prevention of postoperative nausea and vomiting: a prospective, randomised, double-blind, placebo-controlled trial. Acta Anaesthesiol Belg 2008; 59:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           De Oliveira GS Jr, Castro-Alves LJ, Ahmad S, et al. Dexamethasone to prevent postoperative nausea and vomiting: an updated meta-analysis of randomized controlled trials. Anesth Analg 2013; 116:58.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           De Oliveira GS Jr, Almeida MD, Benzon HT, McCarthy RJ. Perioperative single dose systemic dexamethasone for postoperative pain: a meta-analysis of randomized controlled trials. Anesthesiology 2011; 115:575.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lunn TH, Kehlet H. Perioperative glucocorticoids in hip and knee surgery - benefit vs. harm? A review of randomized clinical trials. Acta Anaesthesiol Scand 2013; 57:823.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           DREAMS Trial Collaborators and West Midlands Research Collaborative. Dexamethasone versus standard treatment for postoperative nausea and vomiting in gastrointestinal surgery: randomised controlled trial (DREAMS Trial). BMJ 2017; 357:j1455.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Corcoran TB, Myles PS, Forbes AB, et al. Dexamethasone and Surgical-Site Infection. N Engl J Med 2021; 384:1731.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Corcoran TB, Martin C, O'Loughlin E, et al. Dexamethasone and clinically significant postoperative nausea and vomiting: a prespecified substudy of the randomised perioperative administration of dexamethasone and infection (PADDI) trial. Br J Anaesth 2022; 129:327.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bolac CS, Wallace AH, Broadwater G, et al. The impact of postoperative nausea and vomiting prophylaxis with dexamethasone on postoperative wound complications in patients undergoing laparotomy for endometrial cancer. Anesth Analg 2013; 116:1041.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kurz A, Fleischmann E, Sessler DI, et al. Effects of supplemental oxygen and dexamethasone on surgical site infection: a factorial randomized trial‡. Br J Anaesth 2015; 115:434.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Corcoran T, Kasza J, Short TG, et al. Intraoperative dexamethasone does not increase the risk of postoperative wound infection: a propensity score-matched post hoc analysis of the ENIGMA-II trial (EnDEX). Br J Anaesth 2017; 118:190.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Toner AJ, Ganeshanathan V, Chan MT, et al. Safety of Perioperative Glucocorticoids in Elective Noncardiac Surgery: A Systematic Review and Meta-analysis. Anesthesiology 2017; 126:234.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Polderman JAW, Farhang-Razi V, van Dieren S, et al. Adverse side-effects of dexamethasone in surgical patients - an abridged Cochrane systematic review. Anaesthesia 2019; 74:929.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nazar CE, Lacassie HJ, López RA, Muñoz HR. Dexamethasone for postoperative nausea and vomiting prophylaxis: effect on glycaemia in obese patients with impaired glucose tolerance. Eur J Anaesthesiol 2009; 26:318.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hans P, Vanthuyne A, Dewandre PY, et al. Blood glucose concentration profile after 10 mg dexamethasone in non-diabetic and type 2 diabetic patients undergoing abdominal surgery. Br J Anaesth 2006; 97:164.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tien M, Gan TJ, Dhakal I, et al. The effect of anti-emetic doses of dexamethasone on postoperative blood glucose levels in non-diabetic and diabetic patients: a prospective randomised controlled study. Anaesthesia 2016; 71:1037.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abdelmalak BB, Bonilla AM, Yang D, et al. The hyperglycemic response to major noncardiac surgery and the added effect of steroid administration in patients with and without diabetes. Anesth Analg 2013; 116:1116.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Corcoran TB, O'Loughlin E, Chan MTV, Ho KM. Perioperative ADministration of Dexamethasone And blood Glucose concentrations in patients undergoing elective non-cardiac surgery - the randomised controlled PADDAG trial. Eur J Anaesthesiol 2021; 38:932.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gupta R, Srivastava S, Dhiraaj S, Chovatiya PP. Minimum Effective dose of Dexamethasone in Combination with Midazolam as Prophylaxis against Postoperative Nausea and Vomiting after Laparoscopic Cholecystectomy. Anesth Essays Res 2018; 12:396.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Evaluation of combination antiemetic prophylaxis in high risk emetogenic patients undergoing thyroid surgery: A randomized double-blind study. Egyptian Journal of Anaesthesia 2011; 27:203.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Madan R, Bhatia A, Chakithandy S, et al. Prophylactic dexamethasone for postoperative nausea and vomiting in pediatric strabismus surgery: a dose ranging and safety evaluation study. Anesth Analg 2005; 100:1622.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           White PF, Tang J, Song D, et al. Transdermal scopolamine: an alternative to ondansetron and droperidol for the prevention of postoperative and postdischarge emetic symptoms. Anesth Analg 2007; 104:92.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Apfel CC, Zhang K, George E, et al. Transdermal scopolamine for the prevention of postoperative nausea and vomiting: a systematic review and meta-analysis. Clin Ther 2010; 32:1987.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kranke P, Morin AM, Roewer N, et al. The efficacy and safety of transdermal scopolamine for the prevention of postoperative nausea and vomiting: a quantitative systematic review. Anesth Analg 2002; 95:133.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Seo SW, Suh MK, Chin J, Na DL. Mental confusion associated with scopolamine patch in elderly with mild cognitive impairment (MCI). Arch Gerontol Geriatr 2009; 49:204.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sah N, Ramesh V, Kaul B, et al. Transdermal scopolamine patch in addition to ondansetron for postoperative nausea and vomiting prophylaxis in patients undergoing ambulatory cosmetic surgery. J Clin Anesth 2009; 21:249.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Razeghinejad MR, Myers JS, Katz LJ. Iatrogenic glaucoma secondary to medications. Am J Med 2011; 124:20.
          </a>
         </li>
         <li class="breakAll">
          https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/017874s038lbl.pdf (Accessed on November 06, 2020).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Domino KB, Anderson EA, Polissar NL, Posner KL. Comparative efficacy and safety of ondansetron, droperidol, and metoclopramide for preventing postoperative nausea and vomiting: a meta-analysis. Anesth Analg 1999; 88:1370.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fortney JT, Gan TJ, Graczyk S, et al. A comparison of the efficacy, safety, and patient satisfaction of ondansetron versus droperidol as antiemetics for elective outpatient surgical procedures. S3A-409 and S3A-410 Study Groups. Anesth Analg 1998; 86:731.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yazbeck-Karam VG, Siddik-Sayyid SM, Barakat HB, et al. Haloperidol Versus Ondansetron for Treatment of Established Nausea and Vomiting Following General Anesthesia: A Randomized Clinical Trial. Anesth Analg 2017; 124:438.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Charbit B, Albaladejo P, Funck-Brentano C, et al. Prolongation of QTc interval after postoperative nausea and vomiting treatment by droperidol or ondansetron. Anesthesiology 2005; 102:1094.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chan MT, Choi KC, Gin T, et al. The additive interactions between ondansetron and droperidol for preventing postoperative nausea and vomiting. Anesth Analg 2006; 103:1155.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weissenburger J, Funck-Brentano C, Jaillon P, Charbit B. Droperidol and ondansetron in vitro electrophysiological drug interaction study. Fundam Clin Pharmacol 2009; 23:719.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Feng PH, Chu KS, Lu IC, et al. Haloperidol plus ondansetron prevents postoperative nausea and vomiting in patients undergoing laparoscopic cholecystectomy. Acta Anaesthesiol Taiwan 2009; 47:3.
          </a>
         </li>
         <li class="breakAll">
          Drug Trials Snapshots: BARHEMSYS. Available at: https://www.fda.gov/drugs/development-approval-process-drugs/drug-trials-snapshots-barhemsys (Accessed on June 28, 2020).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kranke P, Eberhart L, Motsch J, et al. I.V. APD421 (amisulpride) prevents postoperative nausea and vomiting: a randomized, double-blind, placebo-controlled, multicentre trial. Br J Anaesth 2013; 111:938.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gan TJ, Kranke P, Minkowitz HS, et al. Intravenous Amisulpride for the Prevention of Postoperative Nausea and Vomiting: Two Concurrent, Randomized, Double-blind, Placebo-controlled Trials. Anesthesiology 2017; 126:268.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Habib AS, Kranke P, Bergese SD, et al. Amisulpride for the Rescue Treatment of Postoperative Nausea or Vomiting in Patients Failing Prophylaxis: A Randomized, Placebo-controlled Phase III Trial. Anesthesiology 2019; 130:203.
          </a>
         </li>
         <li class="breakAll">
          BARHEMSYS label. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209510s000lbl.pdf (Accessed on June 28, 2020).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kranke P, Bergese SD, Minkowitz HS, et al. Amisulpride Prevents Postoperative Nausea and Vomiting in Patients at High Risk: A Randomized, Double-blind, Placebo-controlled Trial. Anesthesiology 2018; 128:1099.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bailard N, Rebello E. Aprepitant and fosaprepitant decrease the effectiveness of hormonal contraceptives. Br J Clin Pharmacol 2018; 84:602.
          </a>
         </li>
         <li class="breakAll">
          Aprepitant capsules, for oral use. US Food &amp; Drug Administration (FDA) approved product information. Revised May, 2022. Available online at: https://www.merck.com/product/usa/pi_circulars/e/emend/emend_pi.pdf (Accessed on March 06, 2023).
         </li>
         <li class="breakAll">
          Fosaprepitant for injection, for intravenous use. US Food &amp; Drug Administration (FDA) approved product information. Revised May, 2022. Available online at: https://www.merck.com/product/usa/pi_circulars/e/emend_iv/emend_iv_lowedta_pi.pdf (Accessed on March 06, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Diemunsch P, Gan TJ, Philip BK, et al. Single-dose aprepitant vs ondansetron for the prevention of postoperative nausea and vomiting: a randomized, double-blind phase III trial in patients undergoing open abdominal surgery. Br J Anaesth 2007; 99:202.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gan TJ, Apfel CC, Kovac A, et al. A randomized, double-blind comparison of the NK1 antagonist, aprepitant, versus ondansetron for the prevention of postoperative nausea and vomiting. Anesth Analg 2007; 104:1082.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Habib AS, Keifer JC, Borel CO, et al. A comparison of the combination of aprepitant and dexamethasone versus the combination of ondansetron and dexamethasone for the prevention of postoperative nausea and vomiting in patients undergoing craniotomy. Anesth Analg 2011; 112:813.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alonso-Damian ER, Anguiano-Garcia MM. Aprepitant to ondansetron in preventing postoperative nausea and vomiting in patients undergoing open cholecystectomy. Revista Mexicana de Anestesiologia 2012; 35:8.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moon HY, Baek CW, Choi GJ, et al. Palonosetron and aprepitant for the prevention of postoperative nausea and vomiting in patients indicated for laparoscopic gynaecologic surgery: a double-blind randomised trial. BMC Anesthesiol 2014; 14:68.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singh PM, Borle A, Rewari V, et al. Aprepitant for postoperative nausea and vomiting: a systematic review and meta-analysis. Postgrad Med J 2016; 92:87.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Murakami C, Kakuta N, Kume K, et al. A Comparison of Fosaprepitant and Ondansetron for Preventing Postoperative Nausea and Vomiting in Moderate to High Risk Patients: A Retrospective Database Analysis. Biomed Res Int 2017; 2017:5703528.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gan TJ, Gu J, Singla N, et al. Rolapitant for the prevention of postoperative nausea and vomiting: a prospective, double-blinded, placebo-controlled randomized trial. Anesth Analg 2011; 112:804.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kranke P, Morin AM, Roewer N, Eberhart LH. Dimenhydrinate for prophylaxis of postoperative nausea and vomiting: a meta-analysis of randomized controlled trials. Acta Anaesthesiol Scand 2002; 46:238.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khalil S, Philbrook L, Rabb M, et al. Ondansetron/promethazine combination or promethazine alone reduces nausea and vomiting after middle ear surgery. J Clin Anesth 1999; 11:596.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chia YY, Lo Y, Liu K, et al. The effect of promethazine on postoperative pain: a comparison of preoperative, postoperative, and placebo administration in patients following total abdominal hysterectomy. Acta Anaesthesiol Scand 2004; 48:625.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen JJ, Frame DG, White TJ. Efficacy of ondansetron and prochlorperazine for the prevention of postoperative nausea and vomiting after total hip replacement or total knee replacement procedures: a randomized, double-blind, comparative trial. Arch Intern Med 1998; 158:2124.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tramèr M, Moore A, McQuay H. Meta-analytic comparison of prophylactic antiemetic efficacy for postoperative nausea and vomiting: propofol anaesthesia vs omitting nitrous oxide vs total i.v. anaesthesia with propofol. Br J Anaesth 1997; 78:256.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Visser K, Hassink EA, Bonsel GJ, et al. Randomized controlled trial of total intravenous anesthesia with propofol versus inhalation anesthesia with isoflurane-nitrous oxide: postoperative nausea with vomiting and economic analysis. Anesthesiology 2001; 95:616.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tramèr M, Moore A, McQuay H. Propofol anaesthesia and postoperative nausea and vomiting: quantitative systematic review of randomized controlled studies. Br J Anaesth 1997; 78:247.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Deutschman CS, Traber KB. Evolution of anesthesiology. Anesthesiology 1996; 85:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gan TJ, Glass PS, Howell ST, et al. Determination of plasma concentrations of propofol associated with 50% reduction in postoperative nausea. Anesthesiology 1997; 87:779.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Erdem AF, Yoruk O, Alici HA, et al. Subhypnotic propofol infusion plus dexamethasone is more effective than dexamethasone alone for the prevention of vomiting in children after tonsillectomy. Paediatr Anaesth 2008; 18:878.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kranke P. Putting the record straight: granisetron's efficacy as an antiemetic 'post-Fujii'. Anaesthesia 2012; 67:1063.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           De Oliveira GS Jr, Castro-Alves LJ, Chang R, et al. Systemic metoclopramide to prevent postoperative nausea and vomiting: a meta-analysis without Fujii's studies. Br J Anaesth 2012; 109:688.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yis U, Ozdemir D, Duman M, Unal N. Metoclopramide induced dystonia in children: two case reports. Eur J Emerg Med 2005; 12:117.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grant MC, Kim J, Page AJ, et al. The Effect of Intravenous Midazolam on Postoperative Nausea and Vomiting: A Meta-Analysis. Anesth Analg 2016; 122:656.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ahn EJ, Kang H, Choi GJ, et al. The Effectiveness of Midazolam for Preventing Postoperative Nausea and Vomiting: A Systematic Review and Meta-Analysis. Anesth Analg 2016; 122:664.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Levin DN, Dulberg Z, Chan AW, et al. A randomized-controlled trial of nabilone for the prevention of acute postoperative nausea and vomiting in elective surgery. Can J Anaesth 2017; 64:385.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hyman JB, Park C, Lin HM, et al. Olanzapine for the Prevention of Postdischarge Nausea and Vomiting after Ambulatory Surgery: A Randomized Controlled Trial. Anesthesiology 2020; 132:1419.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grigio TR, Timmerman H, Martins JVB, et al. Olanzapine as an add-on, pre-operative anti-emetic drug for postoperative nausea or vomiting: a randomised controlled trial. Anaesthesia 2023; 78:1206.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arslan M, Ciçek R, Kalender HÜ, Yilmaz H. Preventing postoperative nausea and vomiting after laparoscopic cholecystectomy: a prospective, randomized, double-blind study. Curr Ther Res Clin Exp 2011; 72:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gan TJ, Sinha AC, Kovac AL, et al. A randomized, double-blind, multicenter trial comparing transdermal scopolamine plus ondansetron to ondansetron alone for the prevention of postoperative nausea and vomiting in the outpatient setting. Anesth Analg 2009; 108:1498.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Habib AS, El-Moalem HE, Gan TJ. The efficacy of the 5-HT3 receptor antagonists combined with droperidol for PONV prophylaxis is similar to their combination with dexamethasone. A meta-analysis of randomized controlled trials. Can J Anaesth 2004; 51:311.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eberhart LH, Morin AM, Bothner U, Georgieff M. Droperidol and 5-HT3-receptor antagonists, alone or in combination, for prophylaxis of postoperative nausea and vomiting. A meta-analysis of randomised controlled trials. Acta Anaesthesiol Scand 2000; 44:1252.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Splinter WM, Rhine EJ. Low-dose ondansetron with dexamethasone more effectively decreases vomiting after strabismus surgery in children than does high-dose ondansetron. Anesthesiology 1998; 88:72.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shende D, Bharti N, Kathirvel S, Madan R. Combination of droperidol and ondansetron reduces PONV after pediatric strabismus surgery more than single drug therapy. Acta Anaesthesiol Scand 2001; 45:756.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Holt R, Rask P, Coulthard KP, et al. Tropisetron plus dexamethasone is more effective than tropisetron alone for the prevention of postoperative nausea and vomiting in children undergoing tonsillectomy. Paediatr Anaesth 2000; 10:181.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Som A, Bhattacharjee S, Maitra S, et al. Combination of 5-HT3 Antagonist and Dexamethasone Is Superior to 5-HT3 Antagonist Alone for PONV Prophylaxis After Laparoscopic Surgeries: A Meta-analysis. Anesth Analg 2016; 123:1418.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Williams BA, Holder-Murray JM, Nettrour JF, et al. Aim for zero: prevention of postoperative nausea and vomiting using an off-patent five-drug multimodal approach. Br J Anaesth 2023; 131:e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rüsch D, Eberhart LH, Wallenborn J, Kranke P. Nausea and vomiting after surgery under general anesthesia: an evidence-based review concerning risk assessment, prevention, and treatment. Dtsch Arztebl Int 2010; 107:733.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vallejo MC, Phelps AL, Ibinson JW, et al. Aprepitant plus ondansetron compared with ondansetron alone in reducing postoperative nausea and vomiting in ambulatory patients undergoing plastic surgery. Plast Reconstr Surg 2012; 129:519.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sinha AC, Singh PM, Williams NW, et al. Aprepitant's prophylactic efficacy in decreasing postoperative nausea and vomiting in morbidly obese patients undergoing bariatric surgery. Obes Surg 2014; 24:225.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Morais LC, Sousa AM, Flora GF, et al. Aprepitant as a fourth antiemetic prophylactic strategy in high-risk patients: a double-blind, randomized trial. Acta Anaesthesiol Scand 2018; 62:483.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Splinter WM. Prevention of vomiting after strabismus surgery in children: dexamethasone alone versus dexamethasone plus low-dose ondansetron. Paediatr Anaesth 2001; 11:591.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee A, Chan SK, Fan LT. Stimulation of the wrist acupuncture point PC6 for preventing postoperative nausea and vomiting. Cochrane Database Syst Rev 2015; :CD003281.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang Y, Zhang C, Yan M, et al. The effectiveness of PC6 acupuncture in the prevention of postoperative nausea and vomiting in children: A systematic review and meta-analysis. Paediatr Anaesth 2020; 30:552.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dune LS, Shiao SY. Metaanalysis of acustimulation effects on postoperative nausea and vomiting in children. Explore (NY) 2006; 2:314.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hines S, Steels E, Chang A, Gibbons K. Aromatherapy for treatment of postoperative nausea and vomiting. Cochrane Database Syst Rev 2012; :CD007598.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gan TJ, Jin Z, Meyer TA. Rescue Treatment of Postoperative Nausea and Vomiting: A Systematic Review of Current Clinical Evidence. Anesth Analg 2022; 135:986.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Czarnetzki C, Albrecht E, Desmeules J, et al. Dexamethasone for the treatment of established postoperative nausea and vomiting: A randomised dose finding trial. Eur J Anaesthesiol 2022; 39:549.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maxwell LG, Kaufmann SC, Bitzer S, et al. The effects of a small-dose naloxone infusion on opioid-induced side effects and analgesia in children and adolescents treated with intravenous patient-controlled analgesia: a double-blind, prospective, randomized, controlled study. Anesth Analg 2005; 100:953.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gan TJ, Ginsberg B, Glass PS, et al. Opioid-sparing effects of a low-dose infusion of naloxone in patient-administered morphine sulfate. Anesthesiology 1997; 87:1075.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mattila K, Toivonen J, Janhunen L, et al. Postdischarge symptoms after ambulatory surgery: first-week incidence, intensity, and risk factors. Anesth Analg 2005; 101:1643.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pan PH, Lee SC, Harris LC. Antiemetic prophylaxis for postdischarge nausea and vomiting and impact on functional quality of living during recovery in patients with high emetic risks: a prospective, randomized, double-blind comparison of two prophylactic antiemetic regimens. Anesth Analg 2008; 107:429.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Efune PN, Minhajuddin A, Szmuk P. Incidence and factors contributing to postdischarge nausea and vomiting in pediatric ambulatory surgical cases. Paediatr Anaesth 2018; 28:257.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 16849 Version 48.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10475299" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Which clinical anesthesia outcomes are important to avoid? The perspective of patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9717590" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Unanticipated admission after ambulatory surgery--a prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10754614" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Cost-effectiveness of prophylactic antiemetic therapy with ondansetron, droperidol, or placebo.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24161560" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Neurochemical mechanisms and pharmacologic strategies in managing nausea and vomiting related to cyclic vomiting syndrome and other gastrointestinal disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21174569" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Nausea, vomiting, and hiccups: a review of mechanisms and treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17620085" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Recent advances in understanding the role of serotonin in gastrointestinal motility in functional bowel disorders: alterations in 5-HT signalling and metabolism in human disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24495419" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Pathophysiological and neurochemical mechanisms of postoperative nausea and vomiting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8692545" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Towards understanding the aetiology and pathophysiology of the emetic reflex: novel approaches to antiemetic drugs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1374316" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Pharmacological agents affecting emesis. A review (Part I).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8267183" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : The postoperative interview: assessing risk factors for nausea and vomiting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10485781" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : A simplified risk score for predicting postoperative nausea and vomiting: conclusions from cross-validations between two centers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9165963" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : A survey of postoperative nausea and vomiting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18042855" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : A prospective evaluation of the POVOC score for the prediction of postoperative vomiting in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23035051" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Evidence-based analysis of risk factors for postoperative nausea and vomiting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10422935" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Can postoperative nausea and vomiting be predicted?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15562045" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : The development and validation of a risk score to predict the probability of postoperative vomiting in pediatric patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15247114" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Applicability of risk scores for postoperative nausea and vomiting in adults to paediatric patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7158749" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Postoperative vomiting in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8435254" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Logistic regression analysis of fixed patient factors for postoperative sickness: a model for risk assessment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12502978" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Difference in risk factors for postoperative nausea and vomiting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22846680" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Who is at risk for postdischarge nausea and vomiting after ambulatory surgery?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26040928" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Does previous chemotherapy-induced nausea and vomiting predict postoperative nausea and vomiting?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12067003" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Volatile anaesthetics may be the main cause of early but not delayed postoperative vomiting: a randomized controlled trial of factorial design.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20151955" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Association between nitrous oxide and the incidence of postoperative nausea and vomiting in adults: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8777095" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Omitting nitrous oxide in general anaesthesia: meta-analysis of intraoperative awareness and postoperative emesis in randomized controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32234276" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Antinausea Protocol Reduces Hospital Length of Stay for Laparoscopic Nissen Fundoplication.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9699101" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : A meta-analysis of nausea and vomiting following maintenance of anaesthesia with propofol or inhalational agents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11050522" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Does etomidate increase postoperative nausea? A double-blind controlled comparison of etomidate in lipid emulsion with propofol for balanced anaesthesia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21773855" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : A systematic review of intravenous ketamine for postoperative analgesia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15271729" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Ketamine as adjuvant analgesic to opioids: a quantitative and qualitative systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27275042" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Intravenous sub-anesthetic ketamine for perioperative analgesia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12393110" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Propofol-ketamine versus propofol-fentanyl for outpatient laparoscopy: comparison of postoperative nausea, emesis, analgesia, and recovery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2141262" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Nitrous oxide, nausea, and vomiting after outpatient gynecologic surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9481978" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Avoidance of nitrous oxide and increased isoflurane during alfentanil based anesthesia decreases the incidence of postoperative nausea.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10418646" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : The impact of nitrous oxide on postoperative nausea and vomiting after desflurane anesthesia for breast surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2523250" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Nitrous oxide does not increase nausea and vomiting following gynaecological laparoscopy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1550279" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Anesthesia for laparoscopic cholecystectomy. Is nitrous oxide contraindicated?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17448844" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Nitrous oxide does not aggravate postoperative emesis after orthognathic surgery in female and nonsmoking patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29150782" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Nitrous oxide added at the end of isoflurane anesthesia hastens early recovery without increasing the risk for postoperative nausea and vomiting: a randomized clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11883387" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Comparison of predictive models for postoperative nausea and vomiting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16861255" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Prevention of postoperative nausea and vomiting by metoclopramide combined with dexamethasone: randomised double blind multicentre trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24401771" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Nitrous oxide-related postoperative nausea and vomiting depends on duration of exposure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16243992" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Postoperative nausea and vomiting are strongly influenced by postoperative opioid use in a dose-related manner.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15915040" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Effects of nonsteroidal antiinflammatory drugs on patient-controlled analgesia morphine side effects: meta-analysis of randomized controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21285082" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Paracetamol and selective and non-selective non-steroidal anti-inflammatory drugs for the reduction in morphine-related side-effects after major surgery: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15681586" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Effects of acetaminophen on morphine side-effects and consumption after major surgery: meta-analysis of randomized controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25516276" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Effect of combining tramadol and morphine in adult surgical patients: a systematic review and meta-analysis of randomized trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28039239" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Non-opioid analgesics in adults after major surgery: systematic review with network meta-analysis of randomized trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16243993" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Does neostigmine administration produce a clinically important increase in postoperative nausea and vomiting?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28236862" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Comparison of the effects of sugammadex and neostigmine on postoperative nausea and vomiting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28806470" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Efficacy and safety of sugammadex versus neostigmine in reversing neuromuscular blockade in adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7577280" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Prevention of vomiting after paediatric strabismus surgery: a systematic review using the numbers-needed-to-treat method.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1510255" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Metoclopramide reduces the incidence of vomiting after tonsillectomy in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8546293" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Postoperative emesis following otoplasty in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12472709" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Incidence of postoperative nausea and vomiting in paediatric ambulatory surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32467512" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Fourth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23433945" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Intravenous acetaminophen reduces postoperative nausea and vomiting: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24356162" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Consensus guidelines for the management of postoperative nausea and vomiting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22593126" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Supplemental intravenous crystalloids for the prevention of postoperative nausea and vomiting: quantitative review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30925195" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Supplemental perioperative intravenous crystalloids for postoperative nausea and vomiting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36178763" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Supplemental intraoperative crystalloids for pediatric postoperative nausea and vomiting-A systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30614143" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : The association between high-volume intraoperative fluid administration and outcomes among pediatric patients undergoing large bowel resection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30649067" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Perioperative Dextrose Infusion and Postoperative Nausea and Vomiting: A Meta-analysis of Randomized Trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32310996" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Effects of intravenous dextrose on preventing postoperative nausea and vomiting: A systematic review and meta-analysis with trial sequential analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27746527" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Impact of different intravenous fluids on blood glucose levels in nondiabetic patients undergoing elective major noncardiac surgeries.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28872580" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Effect of intravenous dextrose administration on postoperative nausea and vomiting in patients undergoing laparoscopic cholecystectomy: A randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33075160" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15190136" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : A factorial trial of six interventions for the prevention of postoperative nausea and vomiting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29223575" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : A comparison between inhalational (Desflurane) and total intravenous anaesthesia (Propofol and dexmedetomidine) in improving postoperative recovery for morbidly obese patients undergoing laparoscopic sleeve gastrectomy: A double-blinded randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9416710" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Efficacy, dose-response, and safety of ondansetron in prevention of postoperative nausea and vomiting: a quantitative systematic review of randomized placebo-controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9416710" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Efficacy, dose-response, and safety of ondansetron in prevention of postoperative nausea and vomiting: a quantitative systematic review of randomized placebo-controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15976206" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Ondansetron oral disintegrating tablets: acceptability and efficacy in children undergoing adenotonsillectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19453311" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Efficacy of orally disintegrating ondansetron in preventing postoperative nausea and vomiting after laparoscopic cholecystectomy: a randomised, double-blind placebo controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18349181" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : The effects of oral ondansetron disintegrating tablets for prevention of at-home emesis in pediatric patients after ear-nose-throat surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10825320" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : A comparison of the costs and efficacy of ondansetron versus dolasetron for antiemetic prophylaxis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8777119" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Effect of ondansetron on nausea and vomiting after middle ear surgery during general anaesthesia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9667348" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : A randomized, double-blind, dose-response study of ondansetron in the prevention of postoperative nausea and vomiting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16037143" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : A double-blind comparison of intravenous ondansetron and placebo for preventing postoperative emesis in 1- to 24-month-old pediatric patients after surgery under general anesthesia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24533393" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Randomized double blind comparative study comparing efficacy of granisetron and ondansetron for the prophylactic control of postoperative nausea and vomiting in patients undergoing middle ear surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : A comparative study of granisetron, dexamethasone, and granisetron plus dexamethasone as prophylactic antiemetic therapy in female patients undergoing breast surgery
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8916825" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : The dose-response relation and cost-effectiveness of granisetron for the prophylaxis of pediatric postoperative emesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10773500" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Pooled analysis of three large clinical trials to determine the optimal dose of dolasetron mesylate needed to prevent postoperative nausea and vomiting. The Dolasetron Prophylaxis Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10773500" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Pooled analysis of three large clinical trials to determine the optimal dose of dolasetron mesylate needed to prevent postoperative nausea and vomiting. The Dolasetron Prophylaxis Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12395171" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : [Tropisetron for prevention of postoperative nausea and vomiting: a quantitative systematic review].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18633025" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Palonosetron exhibits unique molecular interactions with the 5-HT3 receptor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19836386" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Palonosetron triggers 5-HT(3) receptor internalization and causes prolonged inhibition of receptor function.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18633021" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : A randomized, double-blind study to evaluate the efficacy and safety of three different doses of palonosetron versus placebo in preventing postoperative nausea and vomiting over a 72-hour period.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18633022" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : A randomized, double-blind study to evaluate the efficacy and safety of three different doses of palonosetron versus placebo for preventing postoperative nausea and vomiting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27687434" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Efficacy of palonosetron in postoperative nausea and vomiting (PONV)-a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26296300" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Efficacy of palonosetron for preventing postoperative nausea and vomiting: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26408514" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : A Meta-Analysis of Palonosetron for the Prevention of Postoperative Nausea and Vomiting in Adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24717698" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Effect of palonosetron on postoperative nausea and vomiting in children following dental rehabilitation under general anesthesia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21284406" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Different doses of palonosetron for the prevention of postoperative nausea and vomiting in children undergoing strabismus surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18670328" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Effect of ramosetron on patient-controlled analgesia related nausea and vomiting after spine surgery in highly susceptible patients: comparison with ondansetron.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26258145" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Effective Dose of Ramosetron for Prophylaxis of Postoperative Nausea and Vomiting in High-Risk Patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11093989" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : The use of dexamethasone for preventing postoperative nausea and vomiting in females undergoing thyroidectomy: a dose-ranging study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10625002" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Dexamethasone for the prevention of postoperative nausea and vomiting: a quantitative systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18468010" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Methylprednisolone vs. dexamethasone in the prevention of postoperative nausea and vomiting: a prospective, randomised, double-blind, placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23223115" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Dexamethasone to prevent postoperative nausea and vomiting: an updated meta-analysis of randomized controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21799397" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Perioperative single dose systemic dexamethasone for postoperative pain: a meta-analysis of randomized controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23581549" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Perioperative glucocorticoids in hip and knee surgery - benefit vs. harm? A review of randomized clinical trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28420629" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Dexamethasone versus standard treatment for postoperative nausea and vomiting in gastrointestinal surgery: randomised controlled trial (DREAMS Trial).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33951362" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Dexamethasone and Surgical-Site Infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35803757" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Dexamethasone and clinically significant postoperative nausea and vomiting: a prespecified substudy of the randomised perioperative administration of dexamethasone and infection (PADDI) trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23337415" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : The impact of postoperative nausea and vomiting prophylaxis with dexamethasone on postoperative wound complications in patients undergoing laparotomy for endometrial cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25900659" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Effects of supplemental oxygen and dexamethasone on surgical site infection: a factorial randomized trial‡.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28100522" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Intraoperative dexamethasone does not increase the risk of postoperative wound infection: a propensity score-matched post hoc analysis of the ENIGMA-II trial (EnDEX).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27922839" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Safety of Perioperative Glucocorticoids in Elective Noncardiac Surgery: A Systematic Review and Meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30821852" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Adverse side-effects of dexamethasone in surgical patients - an abridged Cochrane systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19401661" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Dexamethasone for postoperative nausea and vomiting prophylaxis: effect on glycaemia in obese patients with impaired glucose tolerance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16698859" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Blood glucose concentration profile after 10 mg dexamethasone in non-diabetic and type 2 diabetic patients undergoing abdominal surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27523051" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : The effect of anti-emetic doses of dexamethasone on postoperative blood glucose levels in non-diabetic and diabetic patients: a prospective randomised controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23558840" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : The hyperglycemic response to major noncardiac surgery and the added effect of steroid administration in patients with and without diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32833858" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Perioperative ADministration of Dexamethasone And blood Glucose concentrations in patients undergoing elective non-cardiac surgery - the randomised controlled PADDAG trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29962605" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Minimum Effective dose of Dexamethasone in Combination with Midazolam as Prophylaxis against Postoperative Nausea and Vomiting after Laparoscopic Cholecystectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : Evaluation of combination antiemetic prophylaxis in high risk emetogenic patients undergoing thyroid surgery: A randomized double-blind study
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15920184" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Prophylactic dexamethasone for postoperative nausea and vomiting in pediatric strabismus surgery: a dose ranging and safety evaluation study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17179250" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : Transdermal scopolamine: an alternative to ondansetron and droperidol for the prevention of postoperative and postdischarge emetic symptoms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21118734" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : Transdermal scopolamine for the prevention of postoperative nausea and vomiting: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12088957" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : The efficacy and safety of transdermal scopolamine for the prevention of postoperative nausea and vomiting: a quantitative systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18834638" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : Mental confusion associated with scopolamine patch in elderly with mild cognitive impairment (MCI).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19502023" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : Transdermal scopolamine patch in addition to ondansetron for postoperative nausea and vomiting prophylaxis in patients undergoing ambulatory cosmetic surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21092926" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : Iatrogenic glaucoma secondary to medications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21092926" id="rid123" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          124 : Iatrogenic glaucoma secondary to medications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10357347" id="rid124" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          125 : Comparative efficacy and safety of ondansetron, droperidol, and metoclopramide for preventing postoperative nausea and vomiting: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9539593" id="rid125" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          126 : A comparison of the efficacy, safety, and patient satisfaction of ondansetron versus droperidol as antiemetics for elective outpatient surgical procedures. S3A-409 and S3A-410 Study Groups.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28002167" id="rid126" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          127 : Haloperidol Versus Ondansetron for Treatment of Established Nausea and Vomiting Following General Anesthesia: A Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15915019" id="rid127" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          128 : Prolongation of QTc interval after postoperative nausea and vomiting treatment by droperidol or ondansetron.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17056948" id="rid128" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          129 : The additive interactions between ondansetron and droperidol for preventing postoperative nausea and vomiting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19678851" id="rid129" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          130 : Droperidol and ondansetron in vitro electrophysiological drug interaction study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19318293" id="rid130" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          131 : Haloperidol plus ondansetron prevents postoperative nausea and vomiting in patients undergoing laparoscopic cholecystectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19318293" id="rid131" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          132 : Haloperidol plus ondansetron prevents postoperative nausea and vomiting in patients undergoing laparoscopic cholecystectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23872464" id="rid132" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          133 : I.V. APD421 (amisulpride) prevents postoperative nausea and vomiting: a randomized, double-blind, placebo-controlled, multicentre trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27902493" id="rid133" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          134 : Intravenous Amisulpride for the Prevention of Postoperative Nausea and Vomiting: Two Concurrent, Randomized, Double-blind, Placebo-controlled Trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30475232" id="rid134" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          135 : Amisulpride for the Rescue Treatment of Postoperative Nausea or Vomiting in Patients Failing Prophylaxis: A Randomized, Placebo-controlled Phase III Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30475232" id="rid135" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          136 : Amisulpride for the Rescue Treatment of Postoperative Nausea or Vomiting in Patients Failing Prophylaxis: A Randomized, Placebo-controlled Phase III Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29543631" id="rid136" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          137 : Amisulpride Prevents Postoperative Nausea and Vomiting in Patients at High Risk: A Randomized, Double-blind, Placebo-controlled Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29266364" id="rid137" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          138 : Aprepitant and fosaprepitant decrease the effectiveness of hormonal contraceptives.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29266364" id="rid138" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          139 : Aprepitant and fosaprepitant decrease the effectiveness of hormonal contraceptives.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29266364" id="rid139" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          140 : Aprepitant and fosaprepitant decrease the effectiveness of hormonal contraceptives.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17540667" id="rid140" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          141 : Single-dose aprepitant vs ondansetron for the prevention of postoperative nausea and vomiting: a randomized, double-blind phase III trial in patients undergoing open abdominal surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17456656" id="rid141" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          142 : A randomized, double-blind comparison of the NK1 antagonist, aprepitant, versus ondansetron for the prevention of postoperative nausea and vomiting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21081776" id="rid142" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          143 : A comparison of the combination of aprepitant and dexamethasone versus the combination of ondansetron and dexamethasone for the prevention of postoperative nausea and vomiting in patients undergoing craniotomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid143" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          144 : Aprepitant to ondansetron in preventing postoperative nausea and vomiting in patients undergoing open cholecystectomy
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25165427" id="rid144" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          145 : Palonosetron and aprepitant for the prevention of postoperative nausea and vomiting in patients indicated for laparoscopic gynaecologic surgery: a double-blind randomised trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26627976" id="rid145" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          146 : Aprepitant for postoperative nausea and vomiting: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29410964" id="rid146" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          147 : A Comparison of Fosaprepitant and Ondansetron for Preventing Postoperative Nausea and Vomiting in Moderate to High Risk Patients: A Retrospective Database Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21385988" id="rid147" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          148 : Rolapitant for the prevention of postoperative nausea and vomiting: a prospective, double-blinded, placebo-controlled randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11939912" id="rid148" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          149 : Dimenhydrinate for prophylaxis of postoperative nausea and vomiting: a meta-analysis of randomized controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10624646" id="rid149" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          150 : Ondansetron/promethazine combination or promethazine alone reduces nausea and vomiting after middle ear surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15101860" id="rid150" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          151 : The effect of promethazine on postoperative pain: a comparison of preoperative, postoperative, and placebo administration in patients following total abdominal hysterectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9801179" id="rid151" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          152 : Efficacy of ondansetron and prochlorperazine for the prevention of postoperative nausea and vomiting after total hip replacement or total knee replacement procedures: a randomized, double-blind, comparative trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9135300" id="rid152" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          153 : Meta-analytic comparison of prophylactic antiemetic efficacy for postoperative nausea and vomiting: propofol anaesthesia vs omitting nitrous oxide vs total i.v. anaesthesia with propofol.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11575532" id="rid153" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          154 : Randomized controlled trial of total intravenous anesthesia with propofol versus inhalation anesthesia with isoflurane-nitrous oxide: postoperative nausea with vomiting and economic analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9135299" id="rid154" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          155 : Propofol anaesthesia and postoperative nausea and vomiting: quantitative systematic review of randomized controlled studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8694353" id="rid155" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          156 : Evolution of anesthesiology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9357878" id="rid156" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          157 : Determination of plasma concentrations of propofol associated with 50% reduction in postoperative nausea.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18768048" id="rid157" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          158 : Subhypnotic propofol infusion plus dexamethasone is more effective than dexamethasone alone for the prevention of vomiting in children after tonsillectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22897144" id="rid158" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          159 : Putting the record straight: granisetron's efficacy as an antiemetic 'post-Fujii'.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23015617" id="rid159" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          160 : Systemic metoclopramide to prevent postoperative nausea and vomiting: a meta-analysis without Fujii's studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15891443" id="rid160" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          161 : Metoclopramide induced dystonia in children: two case reports.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26332858" id="rid161" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          162 : The Effect of Intravenous Midazolam on Postoperative Nausea and Vomiting: A Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26516802" id="rid162" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          163 : The Effectiveness of Midazolam for Preventing Postoperative Nausea and Vomiting: A Systematic Review and Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28160217" id="rid163" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          164 : A randomized-controlled trial of nabilone for the prevention of acute postoperative nausea and vomiting in elective surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32229754" id="rid164" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          165 : Olanzapine for the Prevention of Postdischarge Nausea and Vomiting after Ambulatory Surgery: A Randomized Controlled Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37449978" id="rid165" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          166 : Olanzapine as an add-on, pre-operative anti-emetic drug for postoperative nausea or vomiting: a randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24648571" id="rid166" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          167 : Preventing postoperative nausea and vomiting after laparoscopic cholecystectomy: a prospective, randomized, double-blind study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19372328" id="rid167" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          168 : A randomized, double-blind, multicenter trial comparing transdermal scopolamine plus ondansetron to ondansetron alone for the prevention of postoperative nausea and vomiting in the outpatient setting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15064259" id="rid168" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          169 : The efficacy of the 5-HT3 receptor antagonists combined with droperidol for PONV prophylaxis is similar to their combination with dexamethasone. A meta-analysis of randomized controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11065206" id="rid169" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          170 : Droperidol and 5-HT3-receptor antagonists, alone or in combination, for prophylaxis of postoperative nausea and vomiting. A meta-analysis of randomised controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9447858" id="rid170" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          171 : Low-dose ondansetron with dexamethasone more effectively decreases vomiting after strabismus surgery in children than does high-dose ondansetron.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11421836" id="rid171" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          172 : Combination of droperidol and ondansetron reduces PONV after pediatric strabismus surgery more than single drug therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10736082" id="rid172" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          173 : Tropisetron plus dexamethasone is more effective than tropisetron alone for the prevention of postoperative nausea and vomiting in children undergoing tonsillectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27870735" id="rid173" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          174 : Combination of 5-HT3 Antagonist and Dexamethasone Is Superior to 5-HT3 Antagonist Alone for PONV Prophylaxis After Laparoscopic Surgeries: A Meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36737386" id="rid174" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          175 : Aim for zero: prevention of postoperative nausea and vomiting using an off-patent five-drug multimodal approach.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21079721" id="rid175" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          176 : Nausea and vomiting after surgery under general anesthesia: an evidence-based review concerning risk assessment, prevention, and treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21987042" id="rid176" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          177 : Aprepitant plus ondansetron compared with ondansetron alone in reducing postoperative nausea and vomiting in ambulatory patients undergoing plastic surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23990451" id="rid177" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          178 : Aprepitant's prophylactic efficacy in decreasing postoperative nausea and vomiting in morbidly obese patients undergoing bariatric surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29315462" id="rid178" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          179 : Aprepitant as a fourth antiemetic prophylactic strategy in high-risk patients: a double-blind, randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11696124" id="rid179" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          180 : Prevention of vomiting after strabismus surgery in children: dexamethasone alone versus dexamethasone plus low-dose ondansetron.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26522652" id="rid180" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          181 : Stimulation of the wrist acupuncture point PC6 for preventing postoperative nausea and vomiting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32198961" id="rid181" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          182 : The effectiveness of PC6 acupuncture in the prevention of postoperative nausea and vomiting in children: A systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16846819" id="rid182" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          183 : Metaanalysis of acustimulation effects on postoperative nausea and vomiting in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22513952" id="rid183" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          184 : Aromatherapy for treatment of postoperative nausea and vomiting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36048730" id="rid184" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          185 : Rescue Treatment of Postoperative Nausea and Vomiting: A Systematic Review of Current Clinical Evidence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34799501" id="rid185" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          186 : Dexamethasone for the treatment of established postoperative nausea and vomiting: A randomised dose finding trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15781505" id="rid186" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          187 : The effects of a small-dose naloxone infusion on opioid-induced side effects and analgesia in children and adolescents treated with intravenous patient-controlled analgesia: a double-blind, prospective, randomized, controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9366459" id="rid187" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          188 : Opioid-sparing effects of a low-dose infusion of naloxone in patient-administered morphine sulfate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16301235" id="rid188" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          189 : Postdischarge symptoms after ambulatory surgery: first-week incidence, intensity, and risk factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18633020" id="rid189" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          190 : Antiemetic prophylaxis for postdischarge nausea and vomiting and impact on functional quality of living during recovery in patients with high emetic risks: a prospective, randomized, double-blind comparison of two prophylactic antiemetic regimens.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29436139" id="rid190" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          191 : Incidence and factors contributing to postdischarge nausea and vomiting in pediatric ambulatory surgical cases.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
